S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0

Sabrina Groß; Michael Bitzer; Jörg Albert; Susanne Blödt; Judit Boda-Heggemann; Thomas Brunner; Reiner Caspari; Enrico De Toni; Frank Dombrowski; Matthias Evert; Markus Follmann; Paul Freudenberger; Cihan Gani; Andreas Geier; Eleni Gkika; Martin Götz; Thomas Helmberger; Ralf-Thorsten Hoffmann; Peter Huppert; David Krug; Christian La Fougère; Hauke Lang; Thomas Langer; Philipp Lenz; Tom Lüdde; Andreas Mahnken; Silvio Nadalin; Hoa Huu Phuc Nguyen; Monika Nothacker; Johann Ockenga; Karl Oldhafer; Philipp Paprottka; Philippe Pereira; Thorsten Persigehl; Ruben Plentz; Jürgen Pohl; Heinrich Recken; Peter Reimer; Jutta Riemer; Ulrike Ritterbusch; Elke Roeb; Jörn Rüssel; Barbara Schellhaas; Peter Schirmacher; Hans J. Schlitt; Irene Schmid; Andreas Schuler; Daniel Seehofer; Marianne Sinn; Andreas Stengel; Nadine Steubesand; Christoph Stoll; Andrea Tannapfel; Anne Taubert; Reina Tholen; Jörg Trojan; Ingo van Thiel; Arndt Vogel; Thomas Vogl; Frank Wacker; Oliver Waidmann; Heiner Wedemeyer; Henning Wege; Dane Wildner; Marcus-Alexander Wörns; Peter Galle; Nisar Malek

doi:10.1055/a-2189-8567

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2024; 62(02): e213-e282
DOI: 10.1055/a-2189-8567

Leitlinie

S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0

Sabrina Groß

¹Abteilung für Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Eberhard-Karls Universität, Tübingen

,

Michael Bitzer

¹Abteilung für Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Eberhard-Karls Universität, Tübingen

,

Jörg Albert

²Katharinenhospital, Klinik für Allgemeine Innere Medizin, Gastroenterologie, Hepatologie, Infektiologie und Pneumologie, Stuttgart

,

Susanne Blödt

³Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF), Berlin

,

Judit Boda-Heggemann

⁴Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Mannheim

,

Thomas Brunner

⁵Universitätsklinik für Strahlentherapie-Radioonkologie, Medizinische Universität Graz

,

Reiner Caspari

⁶Klinik Niederrhein, Erkrankungen des Stoffwechsels der Verdauungsorgane und Tumorerkrankungen, Bad Neuenahr-Ahrweiler

,

Enrico De Toni

⁷Medizinische Klinik und Poliklinik II, LMU München

,

Frank Dombrowski

⁸Institut für Pathologie, Universität Greifswald

,

Matthias Evert

⁹Institut für Pathologie, Universität Regensburg

,

Markus Follmann

¹⁰Office des Leitlinienprogrammes Onkologie, Deutsche Krebsgesellschaft e. V., Berlin

,

Paul Freudenberger

¹¹Clinical Guideline Services GmbH (CGS), Berlin/Kiel

,

Cihan Gani

¹²Klinik für Radioonkologie, Universitätsklinikum Tübingen

,

Andreas Geier

¹³Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg

,

Eleni Gkika

¹⁴Klinik für Strahlenheilkunde, Department für Radiologische Diagnostik und Therapie, Universitätsklinikum Freiburg

,

Martin Götz

¹⁵Medizinische Klinik IV – Gastroenterologie/Onkologie, Klinikverbund Südwest, Böblingen

,

Thomas Helmberger

¹⁶Institut für Radiologie, Neuroradiologie und minimal invasive Therapie, München Klinik Bogenhausen

,

Ralf-Thorsten Hoffmann

¹⁷Institut und Poliklinik für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Dresden

,

Peter Huppert

¹⁸Radiologisches Zentrum, Max Grundig Klinik, Bühlerhöhe

,

David Krug

¹⁹Strahlentherapie Campus Kiel, Universitätsklinikum Schleswig-Holstein

,

Christian La Fougère

²⁰Nuklearmedizin und Klinische Molekulare Bildgebung, Eberhard-Karls Universität, Tübingen

,

Hauke Lang

²¹Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Johannes Gutenberg-Universität, Mainz

,

Thomas Langer

¹⁰Office des Leitlinienprogrammes Onkologie, Deutsche Krebsgesellschaft e. V., Berlin

,

Philipp Lenz

²²Zentrale Einrichtung Palliativmedizin, Universitätsklinikum Münster

,

Tom Lüdde

²³Medizinische Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinikum Düsseldorf

,

Andreas Mahnken

²⁴Klinik für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Marburg

,

Silvio Nadalin

²⁵Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Eberhard-Karls Universität, Tübingen

,

Hoa Huu Phuc Nguyen

²⁶Institut für Humangenetik, Ruhr-Universität, Bochum

,

Monika Nothacker

³Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF), Berlin

,

Johann Ockenga

²⁷Medizinische Klinik II, Gesundheit Nord, Klinikverbund Bremen

,

Karl Oldhafer

²⁸Klinik für Leber-, Gallenwegs- und Pankreaschirurgie, Asklepios Klinik Barmbek

,

Philipp Paprottka

²⁹Sektion für Interventionelle Radiologie, Klinikum rechts der Isar, Technische Universität München

,

Philippe Pereira

³⁰Zentrum für Radiologie, Minimal-invasive Therapien und Nuklearmedizin, SLK-Klinken Heilbronn

,

Thorsten Persigehl

³¹Institut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Köln

,

Ruben Plentz

³²Klinik für Innere Medizin, Gesundheit Nord, Klinikverbund Bremen

,

Jürgen Pohl

³³Abteilung für Gastroenterologie, Asklepios Klinik Altona

,

Heinrich Recken

³⁴Hamburger Fern-Hochschule

,

Peter Reimer

³⁵Institut für Diagnostische und Interventionelle Radiologie, Städtisches Klinikum Karlsruhe

,

Jutta Riemer

³⁶Lebertransplantierte e. V.

,

Ulrike Ritterbusch

³⁷Hospizarbeit am Universitätsklinikum Essen

,

Elke Roeb

³⁸Medizinische Klinik II Pneumologie, Nephrologie und Gastroenterologie, Universitätsklinikum Gießen

,

Jörn Rüssel

³⁹Medizinische Klinik IV Hämatologie und Onkologie, Universitätsklinikum Halle (Saale)

,

Barbara Schellhaas

⁴⁰Medizinische Klinik I Gastroenterologie, Pneumologie und Endokrinologie, Friedrich-Alexander-Universität, Erlangen

,

Peter Schirmacher

⁴¹Allgemeine Pathologie und pathologische Anatomie, Universitätsklinikum Heidelberg

,

Hans J. Schlitt

⁴²Klinik und Poliklinik für Chirurgie, Universitätsklinikum Regensburg

,

Irene Schmid

⁴³Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital, LMU München

,

Andreas Schuler

⁴⁴Medizinische Klinik, Gastroenterologie, Alb-Fils-Kliniken, Geislingen an der Steige

,

Daniel Seehofer

⁴⁵Klinik und Poliklinik für Viszeral-, Transplantations-, Thorax- und Gefäßchirurgie, Universitätsklinikum Leipzig

,

Marianne Sinn

⁴⁶II. Medizinische Klinik und Poliklinik (Onkologie, Hämatologie, Knochenmarktransplantation mit Abteilung für Pneumologie), Universitätsklinikum Hamburg-Eppendorf

,

Andreas Stengel

⁴⁷Innere Medizin VI – Psychosomatische Medizin und Psychotherapie, Eberhard-Karls Universität, Tübingen

,

Nadine Steubesand

¹¹Clinical Guideline Services GmbH (CGS), Berlin/Kiel

,

Christoph Stoll

⁴⁸Klinik Herzoghöhe Bayreuth

,

Andrea Tannapfel

⁴⁹Institut für Pathologie, Ruhr-Universität Bochum

,

Anne Taubert

⁵⁰Klinische Sozialarbeit, Universitätsklinikum Heidelberg

,

Reina Tholen

⁵¹Deutscher Bundesverband für Physiotherapie (ZVK) e. V.

,

Jörg Trojan

⁵²Medizinische Klinik 1: Gastroenterologie und Hepatologie, Pneumologie und Allergologie, Endokrinologie und Diabetologie sowie Ernährungsmedizin, Goethe-Universität, Frankfurt

,

Ingo van Thiel

⁵³Deutsche Leberhilfe e. V.

,

Arndt Vogel

⁵⁴Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover

,

Thomas Vogl

⁵⁵Institut für Diagnostische und Interventionelle Radiologie, Goethe-Universität, Frankfurt

,

Frank Wacker

⁵⁶Institut für Diagnostische und Interventionelle Radiologie, Medizinische Hochschule Hannover

,

Oliver Waidmann

⁵⁷Onkologie Bethanien, Frankfurt am Main

,

Heiner Wedemeyer

⁵⁴Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover

,

Henning Wege

⁵⁸Klinik für Allgemeine Innere Medizin, Onkologie/Hämatologie, Gastroenterologie und Infektiologie, Klinikum Esslingen

,

Dane Wildner

⁵⁹Innere Medizin, Krankenhäuser Nürnberger Land GmbH, Standort Lauf

,

Marcus-Alexander Wörns

⁶⁰Klinik für Gastroenterologie, Hämatologie und internistische Onkologie und Endokrinologie, Klinikum Dortmund

,

Peter Galle

⁶¹1. Medizinische Klinik und Poliklinik, Gastroenterologie, Hepatologie, Nephrologie, Rheumatologie, Infektiologie, Johannes Gutenberg-Universität, Mainz

,

Nisar Malek

¹Abteilung für Gastroenterologie, Gastrointestinale Onkologie, Hepatologie, Infektiologie und Geriatrie, Eberhard-Karls Universität, Tübingen

› Institutsangaben

Abstract

Schlüsselwörter

biliäre Karzinome - hepatobiliäre Karzinome - CCA - Gallenblasenkarzinom - Gallengangskarzinom - cholangiozelluläres Karzinom - Diagnostik - Therapie - Risikofaktoren - Cholangiokarzinom

Volltext

Referenzen

Literatur
1 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (03) 1020-1022 https://pubmed.ncbi.nlm.nih.gov/21374666/
2 EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236 https://www.sciencedirect.com/science/article/pii/S0168827818302150
3 Sangiovanni A, Prati GM, Fasani P. et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310
4 Ioannou GN, Splan MF, Weiss NS. et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 938-45-945.e1-4
5 Kanwal F, Kramer JR, Asch SM. et al. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology 2020; 71: 44-55
6 Kanwal F, Kramer JR, Mapakshi S. et al. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology 2018; 155: 1828-1837.e2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279617/pdf/nihms-1504451.pdf
7 EASL-EASD-EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402 https://pubmed.ncbi.nlm.nih.gov/27062661/
8 Frenette CT, Isaacson AJ, Bargellini I. et al. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019; 3: 302-310 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713857/pdf/main.pdf
9 Cucchetti A, Cescon M, Erroi V. et al. Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol 2013; 27: 961-972
10 Brouwer WP, van der Meer AJP, Boonstra A. et al. Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. J Viral Hepat 2017; 24: 1023-1031
11 Papatheodoridis G, Dalekos G, Sypsa V. et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016; 64: 800-806 https://www.sciencedirect.com/science/article/pii/S0168827815007953?via%3Dihub
12 Papatheodoridis GV, Lampertico P, Manolakopoulos S. et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-356
13 Yuen MF, Tanaka Y, Fong DY. et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-88 https://www.sciencedirect.com/science/article/pii/S0168827808005655?via%3Dihub
14 Yang HI, Yuen MF, Chan HL. et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12: 568-574 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70077-8/fulltext
15 Wong VW, Chan SL, Mo F. et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28: 1660-1665
16 Yip TC, Wong GL, Wong VW. et al. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. J Hepatol 2020; 72: 847-854 https://www.sciencedirect.com/science/article/abs/pii/S0168827819307172?via%3Dihub
17 Marrero JA, Kulik LM, Sirlin CB. et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68: 723-750
18 Mittal S, El-Serag HB, Sada YH. et al. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2016; 14: 124-131 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690789/pdf/nihms709433.pdf
19 EASL-ALEH. Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-264
20 Thomas J, Kendall B, Dalais C. et al. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Cancer 2022; 173: 250-262 https://pubmed.ncbi.nlm.nih.gov/35944373/
21 Loosen S, Kostev K, Keitel V. et al. An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD. J Hepatol 2022; 76 (01) 247-248 https://pubmed.ncbi.nlm.nih.gov/34520785/
22 Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019; 156: 1264-1281 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505052/pdf/nihms-1567724.pdf
23 Roeb E, Steffen HM, Bantel H. et al. [S2k Guideline non-alcoholic fatty liver disease]. Z Gastroenterol 2015; 53: 668-723
24 Roeb E, Geier A. Nonalcoholic steatohepatitis (NASH) – current treatment recommendations and future developments. Z Gastroenterol 2019; 57: 508-517
25 Angulo P, Hui JM, Marchesini G. et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854
26 Tanwar S, Trembling PM, Hogan BJ. et al. Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid. J Clin Gastroenterol 2017; 51: 268-277 https://www.ingentaconnect.com/content/wk/jcga/2017/00000051/00000003/art00015;jsessionid=4j79pxsus6e3.x-ic-live-03
27 Kanwal F, Kramer J, Asch SM. et al. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology 2017; 153: 996-1005 https://pubmed.ncbi.nlm.nih.gov/28642197/
28 Masuzaki R, Tateishi R, Yoshida H. et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009; 49: 1954-1961
29 El-Serag HB, Kanwal F, Richardson P. et al. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 2016; 64: 130-137
30 Ioannou GN, Beste LA, Green PK. et al. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology 2019; 157: 1264-1278 https://www.sciencedirect.com/science/article/abs/pii/S001650851941130X?via%3Dihub
31 Omata M, Cheng AL, Kokudo N. et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11: 317-370 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491694/pdf/12072_2017_Article_9799.pdf
32 Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD?. J Hepatol 2018; 68: 326-334 https://www.journal-of-hepatology.eu/article/S0168-8278(17)32353-X/fulltext
33 Simeone JC, Bae JP, Hoogwerf BJ. et al. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol 2017; 9: 679-688 https://pubmed.ncbi.nlm.nih.gov/29276410/
34 Fujiwara N, Friedman SL, Goossens N. et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018; 68: 526-549 https://www.journal-of-hepatology.eu/article/S0168-8278(17)32328-0/pdf
35 Gellert-Kristensen H, Richardson T, Davey SmithG. et al. Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population. Hepatology 2020; 72 (03) 845-856 https://pubmed.ncbi.nlm.nih.gov/32190914/
36 Lithner F, Wetterberg L. Hepatocellular carcinoma in patients with acute intermittent porphyria. Acta Med Scand 1984; 215 (03) 271-274 https://pubmed.ncbi.nlm.nih.gov/6328897/
37 Baravelli C, Sandberg S, Aarsand A. et al. Acute hepatic porphyria and cancer risk: a nationwide cohort study. J Intern Med 2017; 282 (03) 229-240 https://pubmed.ncbi.nlm.nih.gov/28730628/
38 Jang H, Yang H, Ko J. et al. Development of Hepatocellular Carcinoma in Patients with Glycogen Storage Disease: a Single Center Retrospective Study. J Korean Med Sci 2020; 35 (01) e5 https://pubmed.ncbi.nlm.nih.gov/31898434/
39 Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 1993; 152 (Suppl. 01) S63-S70 https://pubmed.ncbi.nlm.nih.gov/8391447/
40 de Fost M, Vom Dahl S, Weverling G. et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 36 (01) 53-58 https://pubmed.ncbi.nlm.nih.gov/16246599/
41 Regenboog M, van Dussen L, Verheij J. et al. Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis 2018; 41 (05) 819-827 https://pubmed.ncbi.nlm.nih.gov/29423829/
42 Bartlett D, Lloyd C, McKiernan P. et al. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J Inherit Metab Dis 2014; 37 (05) 745-752 https://pubmed.ncbi.nlm.nih.gov/24515874/
43 Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int 2016; 36: 1239-1251
44 Papatheodoridis GV, Chan HL, Hansen BE. et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015; 62: 956-967 https://air.unimi.it/retrieve/handle/2434/437611/717191/1-s2.0-S0168827815000045-main.pdf
45 Björkström K, Widman L, Hagström H. Risk of hepatic and extrahepatic cancer in NAFLD: A population-based cohort study. Liver Int 2022; 42 (04) 820-828 https://pubmed.ncbi.nlm.nih.gov/35152526/
46 Poon D, Anderson BO, Chen LT. et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10: 1111-1118
47 Chang MH, Chen CJ, Lai MS. et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859
48 Indolfi G, Easterbrook P, Dusheiko G. et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol 2019; 4: 466-476 https://www.sciencedirect.com/science/article/abs/pii/S2468125319300421?via%3Dihub
49 Inoue M, Yoshimi I, Sobue T. et al. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005; 97: 293-300 https://pubmed.ncbi.nlm.nih.gov/15713964/
50 Bravi F, Tavani A, Bosetti C. et al. Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev 2017; 26: 368-377
51 Aleksandrova K, Bamia C, Drogan D. et al. The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2015; 102: 1498-1508 http://spiral.imperial.ac.uk/bitstream/10044/1/29882/11/Am%20J%20Clin%20Nutr-2015-Aleksandrova-1498-508.pdf
52 Setiawan VW, Wilkens LR, Lu SC. et al. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015; 148: 118-125 https://pubmed.ncbi.nlm.nih.gov/25305507/
53 Saab S, Mallam D, Cox GA. et al. Impact of coffee on liver diseases: a systematic review. Liver Int 2014; 34: 495-504
54 Bhurwal A, Rattan P, Yoshitake S. et al. Inverse Association of Coffee with Liver Cancer Development: An Updated Systematic Review and Meta-analysis. J Gastrointestin Liver Dis 2020; 29: 421-428 https://www.jgld.ro/jgld/index.php/jgld/article/download/805/1593
55 Kennedy OJ, Roderick P, Buchanan R. et al. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open 2017; 7: e013739 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730000/pdf/bmjopen-2016-013739.pdf
56 Filippini T, Malavolti M, Borrelli F. et al. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev 2020; 3: Cd005004
57 Singh S, Fujii LL, Murad MH. et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1573-1584 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900882/pdf/nihms532555.pdf
58 Tseng CH. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver Int 2018; 38: 2018-2027
59 Cunha V, Cotrim HP, Rocha R. et al. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review. Ann Hepatol 2020; 19: 232-237
60 Harris K, Smith L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. Ann Pharmacother 2013; 47: 1348-1352
61 Inzucchi SE, Lipska KJ, Mayo H. et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. Jama 2014; 312: 2668-2675 https://jamanetwork.com/journals/jama/articlepdf/2084896/jrv140019.pdf
62 Zhang X, Harmsen W, Mettler T. et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 2014; 60 (06) 2008-2016 https://pubmed.ncbi.nlm.nih.gov/24798175/
63 Vandenbulcke H, Moreno C, Colle I. et al. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study. J Hepatol 2016; 65: 543-551
64 Ascha MS, Hanouneh IA, Lopez R. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20209604
65 EASL Clinical Practice Guidelines. Management of alcohol-related liver disease. J Hepatol 2018; 69: 154-181
66 Wang ZY, Tao QF, Wang ZH. et al. Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm – A retrospective cohort study. Am J Surg 2020; 219: 717-725 https://www.sciencedirect.com/science/article/abs/pii/S000296101831609X?via%3Dihub
67 Jang JW, Yoo SH, Nam HC. et al. Association of Prophylactic Anti-Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy. Clin Infect Dis 2020; 71: 546-555 https://pubmed.ncbi.nlm.nih.gov/31504352/
68 Yang Y, Wen F, Li J. et al. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Int 2015; 35: 2147-2154
69 Cabibbo G, Celsa C, Calvaruso V. et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol 2019; 71: 265-273 https://www.sciencedirect.com/science/article/abs/pii/S0168827819302211?via%3Dihub
70 Dang H, Yeo YH, Yasuda S. et al. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. Hepatology 2020; 71: 1910-1922
71 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422 https://link.springer.com/content/pdf/10.1007%2Fs00432-004-0552-0.pdf
72 Trevisani F, Santi V, Gramenzi A. et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?. Am J Gastroenterol 2007; 102: 2448-2457
73 Trevisani F, Santi V, Gramenzi A. et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?. Am J Gastroenterol 2007; 102: 2448-2457
74 Fan R, Papatheodoridis G, Sun J. et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol 2020; 73 (06) 1368-1378 https://pubmed.ncbi.nlm.nih.gov/32707225/
75 Johnson P, Innes H, Hughes D. et al. Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify. Br J Cancer 2022; 127 (07) 1263-1269 https://pubmed.ncbi.nlm.nih.gov/35798825/
76 Pocha C, Dieperink E, McMaken KA. et al. Surveillance for hepatocellular cancer with ultrasonography vs computed tomography -- a randomised study. Aliment Pharmacol Ther 2013; 38: 303-312
77 Trinchet JC, Chaffaut C, Bourcier V. et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54: 1987-1997
78 Tzartzeva K, Obi J, Rich NE. et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154: 1706-1718 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927818/pdf/nihms940431.pdf
79 Song BG, Sinn DH, Chi S. et al. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. Eur J Gastroenterol Hepatol 2018; 30: 1447-1452
80 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014; 11: e1001624 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972088/pdf/pmed.1001624.pdf
81 Feng H, Li B, Li Z. et al. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer 2021; 21 (01) 401 https://pubmed.ncbi.nlm.nih.gov/33849479/
82 Ricco G, Cosma C, Bedogni G. et al. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. Cancer Biomark 2020; 29 (02) 189-196 https://pubmed.ncbi.nlm.nih.gov/32623383/
83 Hemken P, Sokoll L, Yang X. et al. Validation of a novel model for the early detection of hepatocellular carcinoma. Clin Proteomics 2019; 16: 2 https://pubmed.ncbi.nlm.nih.gov/30675135/
84 Xu F, Zhang L, He W. et al. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients. Dis Markers 2021; 2021: 8868370 https://pubmed.ncbi.nlm.nih.gov/33628341/
85 Poté N, Cauchy F, Albuquerque M. et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol 2015; 62 (04) 848-854 https://pubmed.ncbi.nlm.nih.gov/25450201/
86 Loglio A, Iavarone M, Facchetti F. et al. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. Liver Int 2020; 40 (08) 1987-1996 https://pubmed.ncbi.nlm.nih.gov/32301212/
87 Best J, Bechmann L, Sowa J. et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2020; 18 (03) 728-735 https://pubmed.ncbi.nlm.nih.gov/31712073/
88 Yang J, Addissie B, Mara K. et al. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev 2019; 28 (03) 531-538 https://pubmed.ncbi.nlm.nih.gov/30464023/
89 Schotten C, Ostertag B, Sowa J. et al. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients. Pharmaceuticals (Basel) 2021; 14 (08) https://pubmed.ncbi.nlm.nih.gov/34451832/
90 Huang C, Fang M, Xiao X. et al. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study. Liver Int 2022; 42 (01) 210-223 https://pubmed.ncbi.nlm.nih.gov/34679250/
91 Tayob N, Kanwal F, Alsarraj A. et al. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clin Gastroenterol Hepatol 2023; 21 (02) 415-423 https://pubmed.ncbi.nlm.nih.gov/35124267/
92 Singal A, Tayob N, Mehta A. et al. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology 2022; 75 (03) 541-549 https://pubmed.ncbi.nlm.nih.gov/34618932/
93 Chan H, Vogel A, Berg T. et al. Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. JGH Open 2022; 6 (05) 292-300 https://pubmed.ncbi.nlm.nih.gov/35601131/
94 Chalasani N, Porter K, Bhattacharya A. et al. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2022; 20 (01) 173-182 https://pubmed.ncbi.nlm.nih.gov/34391922/
95 Loomba R, Lim JK, Patton H. et al. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2020; 158: 1822-1830
96 Petrick JL, Thistle JE, Zeleniuch-Jacquotte A. et al. Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis. Am J Gastroenterol 2018; 113: 1494-1505 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521884/pdf/nihms-1027973.pdf
97 Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut 2020; 69: 1343-1352 https://gut.bmj.com/content/69/7/1343.long
98 Singh S, Allen AM, Wang Z. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-654.e1-9 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208976/pdf/nihms-604814.pdf
99 Sterling RK, Lissen E, Clumeck N. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325
100 Taylor RS, Taylor RJ, Bayliss S. et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology 2020; 158: 1611-1625.e12
101 Rockey DC, Caldwell SH, Goodman ZD. et al. Liver biopsy. Hepatology 2009; 49: 1017-1044
102 Silva MA, Hegab B, Hyde C. et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57: 1592-1596 https://gut.bmj.com/content/gutjnl/57/11/1592.full.pdf
103 Müllhaupt B, Durand F, Roskams T. et al. Is tumor biopsy necessary?. Liver Transpl 2011; 17 (Suppl. 02) S14-S25
104 Fuks D, Cauchy F, Fusco G. et al. Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC. J Hepatol 2014; 61: 589-593
105 Paradis VFM. Tumors of the liver and intrahepatic bile ducts. In: WHO Classification of Tumours Editorial Board WHO-Classification of Tumours (5th ed.) Digestive System Tumours. Lyon: International Agency for Research on Cancer; 2019: 215-264
106 Terminology of nodular hepatocellular lesions. Hepatology 1995; 22: 983-993 https://www.sciencedirect.com/science/article/abs/pii/0270913995903240?via%3Dihub
107 Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-664 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.22709?download=true
108 Burt AD, Alves V, Bedossa P. et al. Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2018; 73: 369-385
109 Edmondson HA, Steiner PE. Primary carcinoma of the liver A study of 100 cases among 48,900 necropsies. Cancer 1954; 7: 462-503 https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142%28195405%297%3A3%3C462%3A%3AAID-CNCR2820070308%3E3.0.CO%3B2-E
110 Nzeako UC, Goodman ZD, Ishak KG. Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma. Cancer 1995; 76: 579-588 https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2819950815%2976%3A4%3C579%3A%3AAID-CNCR2820760407%3E3.0.CO%3B2-D?download=true
111 Di Tommaso L, Franchi G, Park YN. et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007; 45: 725-734
112 Di Tommaso L, Destro A, Seok JY. et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009; 50: 746-754
113 Lee YJ, Lee JM, Lee JS. et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015; 275: 97-109
114 Chen N, Motosugi U, Morisaka H. et al. Added Value of a Gadoxetic Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma. Magn Reson Med Sci 2016; 15: 49-59 https://www.jstage.jst.go.jp/article/mrms/15/1/15_2014-0149/_pdf
115 Granito A, Galassi M, Piscaglia F. et al. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 2013; 37: 355-363
116 Haradome H, Grazioli L, Tinti R. et al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging 2011; 34: 69-78
117 Inoue T, Kudo M, Komuta M. et al. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol 2012; 47: 1036-1047 https://link.springer.com/content/pdf/10.1007%2Fs00535-012-0571-6.pdf
118 Maiwald B, Lobsien D, Kahn T. et al. Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?. PLoS One 2014; 9: e111935 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223069/pdf/pone.0111935.pdf
119 Park VY, Choi JY, Chung YE. et al. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT. Liver Int 2014; 34: 1593-1602
120 Sun HY, Lee JM, Shin CL. et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010; 45: 96-103 https://www.ncbi.nlm.nih.gov/pubmed/20057319
121 Tsurusaki M, Sofue K, Isoda H. et al. Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study. J Gastroenterol 2016; 51: 71-79 https://link.springer.com/content/pdf/10.1007%2Fs00535-015-1097-5.pdf
122 Burrel M, Llovet JM, Ayuso C. et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38: 1034-1042
123 Di Martino M, De Filippis G, De Santis A. et al. Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging. Eur Radiol 2013; 23: 887-896 https://link.springer.com/content/pdf/10.1007%2Fs00330-012-2691-z.pdf
124 Schellhaas B, Bernatik T, Bohle W. et al. Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma – A Prospective Multicenter DEGUM Study. Ultraschall in Med 2021; 42 (02) e20 https://pubmed.ncbi.nlm.nih.gov/32717752/
125 Strobel D, Jung E, Ziesch M. et al. Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS®/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study. Eur Radiol 2021; 31 (10) 7614-7625 https://pubmed.ncbi.nlm.nih.gov/33855588/
126 Schellhaas B, Bernatik T, Dirks K. et al. Contrast-Enhanced Ultrasound Patterns for the Non-invasive Diagnosis of Hepatocellular Carcinoma: A Prospective Multicenter Study in Histologically Proven Liver Lesions in a Real-Life Setting Demonstrating the Benefit of Extended Late Phase Observation. Ultrasound Med Biol 2021; 47 (11) 3170-3180 https://pubmed.ncbi.nlm.nih.gov/34417066/
127 Castilla-Lievre MA, Franco D, Gervais P. et al. Diagnostic value of combining (1)(1)C-choline and (1)(8)F-FDG PET/CT in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2016; 43: 852-859 https://www.ncbi.nlm.nih.gov/pubmed/26577938
128 Chotipanich C, Kunawudhi A, Promteangtrong C. et al. Diagnosis of Hepatocellular Carcinoma Using C11 Choline PET/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT. Asian Pac J Cancer Prev 2016; 17: 3569-3573 https://www.ncbi.nlm.nih.gov/pubmed/27510010
129 Hong G, Suh KS, Suh SW. et al. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol 2016; 64: 852-859 https://www.ncbi.nlm.nih.gov/pubmed/26658686
130 Lin CY, Liao CW, Chu LY. et al. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation. Clin Nucl Med 2017; 42: e183-e187 https://www.ncbi.nlm.nih.gov/pubmed/28114226
131 Khalili K, Kim TK, Jang HJ. et al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011; 54: 723-728 https://www.sciencedirect.com/science/article/pii/S0168827810008147?via%3Dihub
132 Giorgio A, Montesarchio L, Gatti P. et al. Contrast-Enhanced Ultrasound: a Simple and Effective Tool in Defining a Rapid Diagnostic Work-up for Small Nodules Detected in Cirrhotic Patients during Surveillance. J Gastrointestin Liver Dis 2016; 25: 205-211 https://www.ncbi.nlm.nih.gov/pubmed/27308652
133 Schellhaas B, Gortz RS, Pfeifer L. et al. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS. Eur J Gastroenterol Hepatol 2017; 29: 1036-1044 https://www.ncbi.nlm.nih.gov/pubmed/28562394
134 Mitchell DG, Bruix J, Sherman M. et al. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 2015; 61: 1056-1065 https://www.ncbi.nlm.nih.gov/pubmed/25041904
135 Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338
136 Chan AC, Fan ST, Poon RT. et al. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB (Oxford) 2013; 15: 439-448 https://www.hpbonline.org/article/S1365-182X(15)31417-9/pdf
137 Chevret S, Trinchet JC, Mathieu D. et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma Groupe dʼEtude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31: 133-141 https://www.journal-of-hepatology.eu/article/S0168-8278(99)80173-1/fulltext
138 Johnson PJ, Berhane S, Kagebayashi C. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33: 550-558 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322258/pdf/zlj550.pdf
139 Kitai S, Kudo M, Minami Y. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology 2008; 75 (Suppl. 01) 83-90 https://www.karger.com/Article/Abstract/173428
140 Leung TW, Tang AM, Zee B. et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94: 1760-1769
141 Marrero JA, Fontana RJ, Barrat A. et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707-716 https://pubmed.ncbi.nlm.nih.gov/15795889/
142 Pinato DJ, Sharma R, Allara E. et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol 2017; 66: 338-346 https://www.journal-of-hepatology.eu/article/S0168-8278(16)30535-9/pdf
143 Vitale A, Saracino E, Boccagni P. et al. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplant Proc 2009; 41: 1260-1263 https://www.sciencedirect.com/science/article/pii/S0041134509004850?via%3Dihub
144 Yau T, Tang VY, Yao TJ. et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691-1700 https://www.gastrojournal.org/article/S0016-5085(14)00243-1/pdf
145 Sohn JH, Duran R, Zhao Y. et al. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clin Gastroenterol Hepatol 2017; 15: 746-755 https://www.cghjournal.org/article/S1542-3565(16)31049-7/pdf
146 Yang A, Ju W, Yuan X. et al. Comparison between liver resection and liver transplantation on outcomes in patients with solitary hepatocellular carcinoma meeting UNOS criteria: a population-based study of the SEER database. Oncotarget 2017; 8: 97428-97438 https://www.oncotarget.com/article/22134/pdf/
147 Krenzien F, Schmelzle M, Struecker B. et al. Liver Transplantation and Liver Resection for Cirrhotic Patients with Hepatocellular Carcinoma: Comparison of Long-Term Survivals. J Gastrointest Surg 2018; 22: 840-848 https://link.springer.com/content/pdf/10.1007/s11605-018-3690-4.pdf
148 Cherqui D, Laurent A, Mocellin N. et al. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 2009; 250: 738-746
149 Eguchi S, Kanematsu T, Arii S. et al. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 2011; 98: 552-557 https://bjssjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bjs.7393?download=true
150 Sapisochin G, Goldaracena N, Laurence JM. et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology 2016; 64: 2077-2088
151 Mazzaferro V, Battiston C, Sposito C. Pro (With Caution): Extended oncologic indications in liver transplantation. Liver Transpl 2018; 24: 98-103
152 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699
153 Agopian VG, Harlander-Locke MP, Ruiz RM. et al. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. Ann Surg 2017; 266: 525-535
154 Bundesärztekammer. Richtlinien zur Organtransplantation gem § 16 TPG. Deutsches Ärzteblatt 2019;
155 von Felden J, Villanueva A. Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2020; 26: 823-831
156 Yao FY, Ferrell L, Bass NM. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403
157 Mazzaferro V, Llovet JM, Miceli R. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43 https://www.sciencedirect.com/science/article/pii/S1470204508702845?via%3Dihub
158 Sinha J, Mehta N, Dodge JL. et al. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol. Hepatology 2019; 70: 1185-1196
159 Lai Q, Vitale A, Halazun K. et al. Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. Cancers (Basel) 2020; 12 https://res.mdpi.com/d_attachment/cancers/cancers-12-00452/article_deploy/cancers-12-00452-v2.pdf
160 Mehta N, Guy J, Frenette CT. et al. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol 2018; 16: 955-964 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053266/pdf/nihms922574.pdf
161 Otto G, Herber S, Heise M. et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-1267
162 Di Sandro S, Sposito C, Lauterio A. et al. Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients. J Am Coll Surg 2018; 226: 1147-1159 https://www.sciencedirect.com/science/article/abs/pii/S1072751518302199?via%3Dihub
163 Ferrer-Fàbrega J, Forner A, Liccioni A. et al. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology 2016; 63: 839-849
164 Scatton O, Goumard C, Cauchy F. et al. Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation. J Surg Oncol 2015; 111: 1007-1015
165 de Haas RJ, Lim C, Bhangui P. et al. Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: An intention-to-treat analysis. Hepatology 2018; 67: 204-215 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.29468?download=true
166 Bhangui P, Allard MA, Vibert E. et al. Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes?. Ann Surg 2016; 264: 155-163 https://www.ingentaconnect.com/content/wk/sla/2016/00000264/00000001/art00029;jsessionid=5ees0b4oapp5t.x-ic-live-02
167 Pichlmayr R. Is there a place for liver grafting for malignancy?. Transplant Proc 1988; 20: 478-482
168 Roayaie S, Schwartz JD, Sung MW. et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534-540 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.20128?download=true
169 Shetty K, Timmins K, Brensinger C. et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10: 911-918 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.20140?download=true
170 Lee HW, Song GW, Lee SG. et al. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma. Liver Transpl 2018; 24: 1243-1251
171 Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl 2013; 19: 634-645
172 Vibert E, Azoulay D, Hoti E. et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129-137
173 Yao FY, Mehta N, Flemming J. et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61: 1968-1977 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809192/pdf/nihms667031.pdf
174 Hameed B, Mehta N, Sapisochin G. et al. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl 2014; 20: 945-951
175 Heimbach JK, Kulik LM, Finn RS. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358-380
176 Mehta N, Dodge JL, Roberts JP. et al. Alpha-Fetoprotein Decrease from > 1000 to <500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology 2019; 69: 1193-1205 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.30413?download=true
177 EASL Clinical Practice Guidelines. Liver transplantation. J Hepatol 2016; 64: 433-485
178 Martin P, DiMartini A, Feng S. et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59: 1144-1165 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.26972?download=true
179 Adani GL, Baccarani U, Lorenzin D. et al. Elderly versus young liver transplant recipients: patient and graft survival. Transplant Proc 2009; 41: 1293-1294
180 Cross TJ, Antoniades CG, Muiesan P. et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 2007; 13: 1382-1388 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.21181?download=true
181 Grąt M, Kornasiewicz O, Grąt K. et al. Short and long-term outcomes after primary liver transplantation in elderly patients. Pol Przegl Chir 2013; 85: 581-588
182 Aduen JF, Sujay B, Dickson RC. et al. Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years. Mayo Clin Proc 2009; 84: 973-978 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770908/pdf/mayoclinproc_84_11_004.pdf
183 Lipshutz GS, Hiatt J, Ghobrial RM. et al. Outcome of liver transplantation in septuagenarians: a single-center experience. Arch Surg 2007; 142: 775-781 https://jamanetwork.com/journals/jamasurgery/articlepdf/400501/spc70006_775_784.pdf
184 Oezcelik A, Dayangac M, Guler N. et al. Living Donor Liver Transplantation in Patients 70 Years or Older. Transplantation 2015; 99: 1436-1440
185 Taner CB, Ung RL, Rosser BG. et al. Age is not a contraindication for orthotopic liver transplantation: a single institution experience with recipients older than 75 years. Hepatol Int 2012; 6: 403-407 https://link.springer.com/content/pdf/10.1007/s12072-011-9286-7.pdf
186 Huang X, Lu S. Impact of preoperative locoregional therapy on recurrence and patient survival following liver transplantation for hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol 2017; 52: 143-149
187 Kulik L, Heimbach JK, Zaiem F. et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology 2018; 67: 381-400
188 Sneiders D, Houwen T, Pengel LHM. et al. Systematic Review and Meta-Analysis of Posttransplant Hepatic Artery and Biliary Complications in Patients Treated With Transarterial Chemoembolization Before Liver Transplantation. Transplantation 2018; 102: 88-96
189 Clavien PA, Lesurtel M, Bossuyt PM. et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-e22 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417764/pdf/nihms392425.pdf
190 Beal EW, Dittmar KM, Hanje AJ. et al. Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall Survival. Front Oncol 2016; 6: 143
191 Cascales-Campos P, Martinez-Insfran LA, Ramirez P. et al. Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It?. Transplant Proc 2018; 50: 591-594 https://www.sciencedirect.com/science/article/abs/pii/S0041134517309284
192 Finkenstedt A, Vikoler A, Portenkirchner M. et al. Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. Liver Int 2016; 36: 688-695
193 Györi GP, Felsenreich DM, Silberhumer GR. et al. Multimodality locoregional treatment strategies for bridging HCC patients before liver transplantation. Eur Surg 2017; 49: 236-243 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653748/pdf/10353_2017_Article_487.pdf
194 Jianyong L, Jinjing Z, Lunan Y. et al. Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma. Sci Rep 2017; 7: 41624 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290748/pdf/srep41624.pdf
195 Nicolini D, Agostini A, Montalti R. et al. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World J Gastroenterol 2017; 23: 3690-3701 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449426/pdf/WJG-23-3690.pdf
196 Gabr A, Abouchaleh N, Ali R. et al. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. Eur J Radiol 2017; 93: 100-106 https://www.sciencedirect.com/science/article/abs/pii/S0720048X17302012
197 Lai Q, Vitale A, Iesari S. et al. The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation. Liver Transpl 2019; 25: 1023-1033 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.25492?download=true
198 Oligane HC, Xing M, Kim HS. Effect of Bridging Local-Regional Therapy on Recurrence of Hepatocellular Carcinoma and Survival after Orthotopic Liver Transplantation. Radiology 2017; 282: 869-879
199 Millonig G, Graziadei IW, Freund MC. et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-279 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.21033?download=true
200 Cucchetti A, Cescon M, Bigonzi E. et al. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl 2011; 17: 1344-1354 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.22397?download=true
201 Lai Q, Avolio AW, Graziadei I. et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013; 19: 1108-1118 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.23706?download=true
202 Kim DJ, Clark PJ, Heimbach J. et al. Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. Am J Transplant 2014; 14: 1383-1390 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajt.12684?download=true
203 Riaz A, Miller FH, Kulik LM. et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. Jama 2010; 303: 1062-1069 https://jamanetwork.com/journals/jama/articlepdf/185545/joc05021_1062_1069.pdf
204 Wong T, Lee V, Law A. et al. Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant. Hepatology 2021; 74 (05) 2580-2594 https://pubmed.ncbi.nlm.nih.gov/34091914/
205 Sapisochin G, Barry A, Doherty M. et al. Stereotactic body radiotherapy vs TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma An intention-to-treat analysis. J Hepatol 2017; 67 (01) 92-99 https://pubmed.ncbi.nlm.nih.gov/28257902/
206 Degroote H, Callebout E, Iesari S. et al. Extended criteria for liver transplantation in hepatocellular carcinoma A retrospective, multicentric validation study in Belgium. Surg Oncol 2020; https://pubmed.ncbi.nlm.nih.gov/31630912/
207 Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl 2015; 21: 1142-1152 https://deepblue.lib.umich.edu/bitstream/handle/2027.42/113108/lt24169.pdf?sequence=1
208 Chapman WC, Garcia-Aroz S, Vachharajani N. et al. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions. J Am Coll Surg 2017; 224: 610-621 https://www.sciencedirect.com/science/article/abs/pii/S1072751516317240
209 Graziadei I, Zoller H, Fickert P. et al. Indications for liver transplantation in adults: Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). Wien Klin Wochenschr 2016; 128: 679-690 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052293/pdf/508_2016_Article_1046.pdf
210 Mazzaferro V, Sposito C, Zhou J. et al. Metroticket 20 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology 2018; 154: 128-139 https://www.gastrojournal.org/article/S0016-5085(17)36184-X/fulltext
211 Halazun KJ, Tabrizian P, Najjar M. et al. Is it Time to Abandon the Milan Criteria? Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies. Ann Surg 2018; 268: 690-699
212 Hong SK, Lee KW, Kim HS. et al. Living donor liver transplantation for hepatocellular carcinoma in Seoul National University. Hepatobiliary Surg Nutr 2016; 5: 453-460
213 Kornberg A, Schernhammer M, Friess H. (18)F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017; 5: 224-234
214 Assalino M, Terraz S, Grat M. et al. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion – a multi-center retrospective cohort study. Transpl Int 2020; 33: 567-575
215 Parikh ND, Yopp A, Singal AG. Controversies in criteria for liver transplantation in hepatocellular carcinoma. Curr Opin Gastroenterol 2016; 32: 182-188
216 Salem R, Gordon AC, Mouli S. et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology 2016; 151: 1155-1163.e2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124387/pdf/nihms813288.pdf
217 Ettorre GM, Levi Sandri GB, Laurenzi A. et al. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World J Surg 2017; 41: 241-249 https://link.springer.com/content/pdf/10.1007/s00268-016-3682-z.pdf
218 Schwacha-Eipper B, Minciuna I, Banz V. et al. Immunotherapy as a downstaging therapy for liver transplantation. Hepatology 2020;
219 Golse N, Radenne S, Rode A. et al. Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review. Exp Clin Transplant 2018; 16: 227-236
220 Hoffmann K, Ganten T, Gotthardtp D. et al. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients – a prospective, randomized, double-blind, phase III trial. BMC Cancer 2015; 15: 392 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449604/pdf/12885_2015_Article_1373.pdf
221 Berenguer M, Burra P, Ghobrial M. et al. Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 2020; 104: 1143-1149
222 Verna EC, Patel YA, Aggarwal A. et al. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020; 20: 333-347 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajt.15697?download=true
223 Vivarelli M, Cucchetti A, Piscaglia F. et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11: 497-503 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.20391?download=true
224 Vivarelli M, Cucchetti A, La Barba G. et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857-862
225 Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC. et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013; 59: 1193-1199
226 Decaens T, Roudot-Thoraval F, Bresson-Hadni S. et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006; 12: 7319-7325 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087490/pdf/WJG-12-7319.pdf
227 Tan PS, Muthiah MD, Koh T. et al. Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation. Transplantation 2019; 103: 470-480
228 Duvoux C, Toso C. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?. Transplant Rev (Orlando) 2015; 29: 168-174
229 Tarantino G, Magistri P, Ballarin R. et al. Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature. Front Pharmacol 2016; 7: 387 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073152/pdf/fphar-07-00387.pdf
230 Teperman L, Moonka D, Sebastian A. et al. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl 2013; 19: 675-689 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.23658?download=true
231 De Simone P, Metselaar HJ, Fischer L. et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009; 15: 1262-1269 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.21827?download=true
232 Fischer L, Saliba F, Kaiser GM. et al. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. Transplantation 2015; 99: 1455-1462
233 Geissler EK, Schnitzbauer AA, Zülke C. et al. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation 2016; 100: 116-125
234 Trevisani F, Frigerio M, Santi V. et al. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010; 42: 341-347
235 Paradis V, Zalinski S, Chelbi E. et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-859 https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.22734
236 Piscaglia F, Svegliati-Baroni G, Barchetti A. et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 2016; 63: 827-838
237 Ertle J, Dechêne A, Sowa JP. et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-2443 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.25797?download=true
238 Zhou Y, Lei X, Wu L. et al. Outcomes of hepatectomy for noncirrhotic hepatocellular carcinoma: a systematic review. Surg Oncol 2014; 23: 236-242
239 Faber W, Sharafi S, Stockmann M. et al. Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver. Surgery 2013; 153: 510-517
240 Cauchy F, Zalinski S, Dokmak S. et al. Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg 2013; 100: 113-121 https://bjssjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bjs.8963?download=true
241 Dasari BV, Kamarajah SK, Hodson J. et al. Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver. HPB (Oxford) 2020; 22: 383-390 https://www.sciencedirect.com/science/article/abs/pii/S1365182X19306215?via%3Dihub
242 Ju M, Yopp AC. The Utility of Anatomical Liver Resection in Hepatocellular Carcinoma: Associated with Improved Outcomes or Lack of Supportive Evidence?. Cancers (Basel) 2019; 11 https://res.mdpi.com/d_attachment/cancers/cancers-11-01441/article_deploy/cancers-11-01441.pdf
243 Moris D, Tsilimigras DI, Kostakis ID. et al. Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis. Eur J Surg Oncol 2018; 44: 927-938 https://www.sciencedirect.com/science/article/abs/pii/S0748798318310242?via%3Dihub
244 Arnaoutakis DJ, Mavros MN, Shen F. et al. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Ann Surg Oncol 2014; 21: 147-154 https://link.springer.com/content/pdf/10.1245/s10434-013-3211-3.pdf
245 Lang H, Sotiropoulos GC, Brokalaki EI. et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 2007; 205: 27-36
246 Bège T, Le TreutYP, Hardwigsen J. et al. Prognostic factors after resection for hepatocellular carcinoma in nonfibrotic or moderately fibrotic liver A 116-case European series. J Gastrointest Surg 2007; 11: 619-625 https://link.springer.com/content/pdf/10.1007/s11605-006-0023-9.pdf
247 Teegen EM, Mogl MT, Pratschke J. et al. Adrenal Metastasis of Hepatocellular Carcinoma in Patients following Liver Resection or Liver Transplantation: Experience from a Tertiary Referral Center. Int J Surg Oncol 2018; 2018: 4195076 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087597/pdf/IJSO2018-4195076.pdf
248 Wang YY, Zhao XH, Ma L. et al. Comparison of the ability of Child-Pugh score, MELD score, and ICG-R15 to assess preoperative hepatic functional reserve in patients with hepatocellular carcinoma. J Surg Oncol 2018; 118: 440-445 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jso.25184?download=true
249 Rubin TM, Heyne K, Luchterhand A. et al. Kinetic validation of the LiMAx test during 10 000 intravenous (13)C-methacetin breath tests. J Breath Res 2017; 12: 016005 https://iopscience.iop.org/article/10.1088/1752-7163/aa820b
250 Stockmann M, Lock JF, Riecke B. et al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 2009; 250: 119-125
251 Huang Z, Huang J, Zhou T. et al. Prognostic value of liver stiffness measurement for the liver-related surgical outcomes of patients under hepatic resection: A meta-analysis. PLoS One 2018; 13: e0190512 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764309/pdf/pone.0190512.pdf
252 Simonetto DA, Liu M, Kamath PS. Portal Hypertension and Related Complications: Diagnosis and Management. Mayo Clin Proc 2019; 94: 714-726 https://www.sciencedirect.com/science/article/abs/pii/S0025619618310085?via%3Dihub
253 Roayaie S, Jibara G, Tabrizian P. et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 2015; 62: 440-451 https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.27745
254 Ishizawa T, Hasegawa K, Aoki T. et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-1916 https://www.sciencedirect.com/science/article/pii/S0016508508004277?via%3Dihub
255 Torzilli G, Belghiti J, Kokudo N. et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? an observational study of the HCC East-West study group. Ann Surg 2013; 257: 929-937
256 Koh YX, Tan HL, Lye WK. et al. Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence. World J Hepatol 2018; 10: 433-447 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033716/pdf/WJH-10-433.pdf
257 Zaydfudim VM, Vachharajani N, Klintmalm GB. et al. Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria. Ann Surg 2016; 264: 650-658 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279918/pdf/nihms-835604.pdf
258 Tsilimigras DI, Bagante F, Moris D. et al. Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol 2020; 27: 2321-2331 https://link.springer.com/content/pdf/10.1245/s10434-020-08452-3.pdf
259 Pang TC, Lam VW. Surgical management of hepatocellular carcinoma. World J Hepatol 2015; 7: 245-252 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342606/pdf/WJH-7-245.pdf
260 Feng X, Su Y, Zheng S. et al. A double blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence. HPB (Oxford) 2017; 19: 667-674
261 Wakabayashi G, Cherqui D, Geller DA. et al. Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg 2015; 261: 619-629
262 Cherqui D, Soubrane O. Laparoscopic Liver Resection: An Ongoing Revolution. Ann Surg 2017; 265: 864-865 https://www.ingentaconnect.com/content/wk/sla/2017/00000265/00000005/art00019
263 Andreou A, Struecker B, Raschzok N. et al. Minimal-invasive versus open hepatectomy for hepatocellular carcinoma: Comparison of postoperative outcomes and long-term survivals using propensity score matching analysis. Surg Oncol 2018; 27: 751-758 https://www.sciencedirect.com/science/article/abs/pii/S0960740418302512?via%3Dihub
264 Haber PK, Wabitsch S, Krenzien F. et al. Laparoscopic liver surgery in cirrhosis – Addressing lesions in posterosuperior segments. Surg Oncol 2019; 28: 140-144 https://www.sciencedirect.com/science/article/abs/pii/S0960740418304614?via%3Dihub
265 Levi Sandri GB, Ettorre GM, Aldrighetti L. et al. Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry. Surg Endosc 2019; 33: 1451-1458 https://link.springer.com/content/pdf/10.1007/s00464-018-6426-3.pdf
266 Felli E, Cillo U, Pinna AD. et al. Salvage liver transplantation after laparoscopic resection for hepatocellular carcinoma: a multicenter experience. Updates Surg 2015; 67: 215-222 https://link.springer.com/content/pdf/10.1007/s13304-015-0323-2.pdf
267 Chen MS, Li JQ, Zheng Y. et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-328 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1448947/pdf/20060300s00006p321.pdf
268 Feng K, Yan J, Li X. et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012; 57: 794-802 https://www.sciencedirect.com/science/article/pii/S0168827812003613?via%3Dihub
269 Huang J, Yan L, Cheng Z. et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252: 903-912
270 Ng KKC, Chok KSH, Chan ACY. et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg 2017; 104: 1775-1784
271 Yin L, Li H, Li AJ. et al. Partial hepatectomy vs transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol 2014; 61: 82-88 https://www.sciencedirect.com/science/article/pii/S0168827814001561?via%3Dihub
272 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60 https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0030-1247132.pdf
273 Wahab MA, Shehta A, Hamed H. et al. Predictors of recurrence in hepatitis C virus related hepatocellular carcinoma after hepatic resection: a retrospective cohort study. Eurasian J Med 2014; 46: 36-41 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261437/pdf/eajm-46-1-36.pdf
274 Ramacciato G, Mercantini P, Nigri GR. et al. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology 2006; 53: 898-903
275 Di Costanzo GG, Tortora R, DʼAdamo G. et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. J Gastroenterol Hepatol 2015; 30: 559-565
276 Cucchetti A, Piscaglia F, Cescon M. et al. An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Dig Liver Dis 2014; 46: 257-263
277 Nishikawa H, Inuzuka T, Takeda H. et al. Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol 2011; 11: 143 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260104/pdf/1471-230X-11-143.pdf
278 Uhlig J, Sellers CM, Stein SM. et al. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. Eur Radiol 2019; 29: 2679-2689 https://link.springer.com/article/10.1007/s00330-018-5902-4
279 Salmi A, Turrini R, Lanzani G. et al. Radiofrequency ablation of hepatocellular carcinoma in patients with and without cirrhosis. J Ultrasound 2009; 12: 118-124 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552707/pdf/main.pdf
280 Mohanty S, Rajaram R, Bilimoria KY. et al. Assessment of non-surgical versus surgical therapy for localized hepatocellular carcinoma. J Surg Oncol 2016; 113: 175-180
281 Yamauchi R, Takata K, Shinagawa Y. et al. Hepatocellular Carcinoma Arising in a Non-cirrhotic Liver with Secondary Hemochromatosis. Intern Med 2019; 58: 661-665 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443541/pdf/1349-7235-58-0661.pdf
282 Livraghi T, Goldberg SN, Lazzaroni S. et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655-661
283 Lencioni RA, Allgaier HP, Cioni D. et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-240
284 Lin SM, Lin CJ, Lin CC. et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤4 cm. Gastroenterology 2004; 127: 1714-1723 https://www.sciencedirect.com/science/article/abs/pii/S0016508504015720?via%3Dihub
285 Bruix J, Sherman M, Llovet JM. et al. Clinical management of hepatocellular carcinoma Conclusions of the Barcelona-2000 EASL conference European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430
286 Shiina S, Teratani T, Obi S. et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-130 https://www.sciencedirect.com/science/article/abs/pii/S0016508505006918?via%3Dihub
287 Brunello F, Veltri A, Carucci P. et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol 2008; 43: 727-735 https://www.tandfonline.com/doi/pdf/10.1080/00365520701885481?needAccess=true
288 Lin SM, Lin CJ, Lin CC. et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151-1156 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774888/pdf/gut05401151.pdf
289 Shiina S, Teratani T, Obi S. et al. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002; 62 Suppl 1: 64-68 https://www.karger.com/Article/Pdf/48278
290 Hara K, Takeda A, Tsurugai Y. et al. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis. Hepatology 2019; 69: 2533-2545 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.30591?download=true
291 Peng ZW, Zhang YJ, Chen MS. et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31: 426-432
292 Liu H, Wang ZG, Fu SY. et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg 2016; 103: 348-356 https://bjssjournals.onlinelibrary.wiley.com/doi/full/10.1002/bjs.10061
293 Endo K, Kuroda H, Oikawa T. et al. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. Scand J Gastroenterol 2018; 53: 1575-1583 https://www.tandfonline.com/doi/full/10.1080/00365521.2018.1548645
294 Fukutomi S, Nomura Y, Nakashima O. et al. Evaluation of hepatocellular carcinoma spread via the portal system by 3-dimensional mapping. HPB (Oxford) 2017; 19: 1119-1125
295 Smolock AR, Cristescu MM, Hinshaw A. et al. Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone. Abdom Radiol (NY) 2018; 43: 2497-2504 https://link.springer.com/content/pdf/10.1007/s00261-018-1464-9.pdf
296 Bonomo G, Della VignaP, Monfardini L. et al. Combined therapies for the treatment of technically unresectable liver malignancies: bland embolization and radiofrequency thermal ablation within the same session. Cardiovasc Intervent Radiol 2012; 35: 1372-1379 https://link.springer.com/content/pdf/10.1007/s00270-012-0341-0.pdf
297 Lo CM, Ngan H, Tso WK. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171 https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1053/jhep.2002.33156
298 Lammer J, Malagari K, Vogl T. et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52 https://www.zora.uzh.ch/id/eprint/24207/1/Lammer_CardiovascInterventRadiol_2010_V.pdf
299 Golfieri R, Giampalma E, Renzulli M. et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111: 255-264 https://iris.unito.it/retrieve/handle/2318/149077/25760/art%20Doxorubicina-Tace%202014.pdf
300 Yamada R, Bassaco B, Bracewell S. et al. Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC). J Gastrointest Oncol 2019; 10: 348-353
301 Llovet JM, Real MI, Montana X. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739 https://www.sciencedirect.com/science/article/pii/S014067360208649X?via%3Dihub
302 Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020; 1: Cd011313
303 Yang J, Wang J, Zhou H. et al. Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial. Endoscopy 2018; 50: 751-760 https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0043-124870.pdf
304 Ludwig JM, Zhang D, Xing M. et al. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus (90)Y-radioembolization for hepatocellular carcinoma. Eur Radiol 2017; 27: 2031-2041 https://link.springer.com/content/pdf/10.1007%2Fs00330-016-4548-3.pdf
305 Casadei GardiniA, Tamburini E, Inarrairaegui M. et al. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther 2018; 11: 7315-7321 https://www.dovepress.com/getfile.php?fileID=45631
306 Kolligs FT, Bilbao JI, Jakobs T. et al. Pilot randomized trial of selective internal radiation therapy vs chemoembolization in unresectable hepatocellular carcinoma. Liver Int 2015; 35: 1715-1721 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/liv.12750?download=true
307 Katsanos K, Kitrou P, Spiliopoulos S. et al. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One 2017; 12: e0184597 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608206/pdf/pone.0184597.pdf
308 Pitton MB, Kloeckner R, Ruckes C. et al. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2015; 38: 352-360 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355443/pdf/270_2014_Article_1012.pdf
309 Lobo L, Yakoub D, Picado O. et al. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol 2016; 39: 1580-1588 https://link.springer.com/content/pdf/10.1007/s00270-016-1426-y.pdf
310 Salem R, Gilbertsen M, Butt Z. et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013; 11: 1358-1365.e1 https://www.sciencedirect.com/science/article/abs/pii/S1542356513005971?via%3Dihub
311 Sangro B, Maini CL, Ettorre GM. et al. Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. Eur J Nucl Med Mol Imaging 2018; 45: 1721-1730 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097757/pdf/259_2018_Article_3968.pdf
312 Johnson GE, Monsky WL, Valji K. et al. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol 2016; 27: 1123-1129
313 Hilgard P, Hamami M, Fouly AE. et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52: 1741-1749 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.23944?download=true
314 Sangro B, Carpanese L, Cianni R. et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54: 868-878 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.24451?download=true
315 Kulik LM, Carr BI, Mulcahy MF. et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.21980?download=true
316 Mazzaferro V, Sposito C, Bhoori S. et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013; 57: 1826-1837 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.26014?download=true
317 Salem R, Lewandowski RJ, Mulcahy MF. et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64
318 Rim CH, Kim CY, Yang DS. et al. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiother Oncol 2018; 129: 112-122 https://www.sciencedirect.com/science/article/abs/pii/S0167814017327305?via%3Dihub
319 Salem R, Padia S, Lam M. et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 2019; 46 (08) 1695-1704 https://pubmed.ncbi.nlm.nih.gov/31098749/
320 Levillain H, Bagni O, Deroose C. et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging 2021; 48 (05) 1570-1584 https://pubmed.ncbi.nlm.nih.gov/33433699/
321 Garin E, Tselikas L, Guiu B. et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6 (01) 17-29 https://pubmed.ncbi.nlm.nih.gov/33166497/
322 Salem R, Johnson G, Kim E. et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology 2021; 74 (05) 2342-2352 https://pubmed.ncbi.nlm.nih.gov/33739462/
323 Vilgrain V, Pereira H, Assenat E. et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. The Lancet Oncology 2017; 18: 1624-1636
324 Chow PKH, Gandhi M, Tan SB. et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 2018; 36: 1913-1921 https://www.ncbi.nlm.nih.gov/pubmed/29498924
325 Omata M, Cheng A, Kokudo N. et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11 (04) 317-370 https://pubmed.ncbi.nlm.nih.gov/28620797/
326 Vogel A, Cervantes A, Chau I. et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv238-iv255
327 Eriguchi T, Takeda A, Tateishi Y. et al. Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta-analysis of propensity score studies. Hepatol Res 2021; 51 (07) 813-822 https://pubmed.ncbi.nlm.nih.gov/33856722/
328 Rim C, Lee J, Kim S. et al. Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis. JHEP Rep 2023; 5 (01) 100594 https://pubmed.ncbi.nlm.nih.gov/36561128/
329 Craig T, Xiao Y, McNulty S. et al. Insights From Image Guided Radiation Therapy Credentialing for the NRG Oncology RTOG 1112 Liver Stereotactic Body Radiation Therapy Trial. Pract Radiat Oncol 2023; https://pubmed.ncbi.nlm.nih.gov/36581199/
330 Rim C, Kim H, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiother Oncol 2019; 131: 135-144 https://pubmed.ncbi.nlm.nih.gov/30773180/
331 Sapir E, Tao Y, Schipper MJ. et al. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2018; 100: 122-130 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818982/pdf/nihms942371.pdf
332 Brunner T, Bettinger D, Schultheiss M. et al. Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study). Front Oncol 2021; 11: 653141 https://pubmed.ncbi.nlm.nih.gov/33816309/
333 Guckenberger M, Baus W, Blanck O. et al. Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Strahlenther Onkol 2020; 196 (05) 417-420 https://pubmed.ncbi.nlm.nih.gov/32211940/
334 Mizumoto M, Tokuuye K, Sugahara S. et al. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys 2008; 71: 462-467
335 Fukumitsu N, Sugahara S, Nakayama H. et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009; 74: 831-836
336 Sugahara S, Oshiro Y, Nakayama H. et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010; 76: 460-466
337 Kim T, Park J, Kim Y. et al. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat 2015; 47 (01) 34-45 https://pubmed.ncbi.nlm.nih.gov/25381830/
338 Nakayama H, Sugahara S, Fukuda K. et al. Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract. Int J Radiat Oncol Biol Phys 2011; 80: 992-995
339 Bush DA, Smith JC, Slater JD. et al. Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis. Int J Radiat Oncol Biol Phys 2016; 95: 477-482
340 Hong TS, Wo JY, Yeap BY. et al. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 2016; 34: 460-468 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872014/pdf/JCO642710.pdf
341 Mizumoto M, Oshiro Y, Okumura T. et al. Proton Beam Therapy for Hepatocellular Carcinoma: A Review of the University of Tsukuba Experience. Int J Part Ther 2016; 2 (04) 570-578 https://pubmed.ncbi.nlm.nih.gov/31772968/
342 Mohnike K, Wieners G, Schwartz F. et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 2010; 78: 172-179
343 Mohnike K, Steffen IG, Seidensticker M. et al. Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial. Cardiovasc Intervent Radiol 2019; 42: 239-249 https://link.springer.com/content/pdf/10.1007/s00270-018-2127-5.pdf
344 Collettini F, Schreiber N, Schnapauff D. et al. CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma. Strahlenther Onkol 2015; 191: 405-412 https://link.springer.com/content/pdf/10.1007/s00066-014-0781-3.pdf
345 Comito T, Loi M, Franzese C. et al. Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360). Curr Oncol 2022; 29 (11) 8802-8813 https://pubmed.ncbi.nlm.nih.gov/36421345/
346 Buckstein M, Kim E, Özbek U. et al. Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable Single Large Hepatocellular Carcinoma: Results From a Prospective Phase 2 Trial. Int J Radiat Oncol Biol Phys 2022; 114 (02) 221-230 https://pubmed.ncbi.nlm.nih.gov/35643250/
347 Yoon S, Ryoo B, Lee S. et al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol 2018; 4 (05) 661-669 https://pubmed.ncbi.nlm.nih.gov/29543938/
348 Huo Y, Eslick G. Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol 2015; 1 (06) 756-765 https://pubmed.ncbi.nlm.nih.gov/26182200/
349 Santillan C, Chernyak V, Sirlin C. LI-RADS categories: concepts, definitions, and criteria. Abdom Radiol (NY) 2018; 43: 101-110
350 Santillan C, Fowler K, Kono Y. et al. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol (NY) 2018; 43: 75-81
351 Takahashi S, Kudo M, Chung H. et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 2007; 72 (Suppl. 01) 98-103 https://www.karger.com/Article/Pdf/111714
352 Guglielmi A, Ruzzenente A, Pachera S. et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol 2008; 103: 597-604
353 Yoon JH, Lee EJ, Cha SS. et al. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol 2010; 21: 348-356
354 Vauthey JN, Dixon E, Abdalla EK. et al. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010; 12: 289-299 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951814/pdf/hpb0012-0289.pdf
355 Schima W, Ba-Ssalamah A, Kurtaran A. et al. Post-treatment imaging of liver tumours. Cancer Imaging 2007; 7: S28-S36 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727978/pdf/ci079047.pdf
356 Frieser M, Kiesel J, Lindner A. et al. Efficacy of contrast-enhanced US versus CT or MRI for the therapeutic control of percutaneous radiofrequency ablation in the case of hepatic malignancies. Ultraschall in Med 2011; 32: 148-153 https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0029-1245934.pdf
357 Schacherer D, Girlich C, Jung ME. et al. Transabdominal ultrasound with echoenhancement by contrast media in the diagnosis of hepatocellular carcinoma. Dig Dis 2009; 27: 109-113 https://www.karger.com/Article/Pdf/218342
358 Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 2008; 48: 848-857 https://www.sciencedirect.com/science/article/pii/S0168827808001244?via%3Dihub
359 Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 2010; 33: 11-17 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816824/pdf/270_2009_Article_9736.pdf
360 Tsai MC, Wang JH, Hung CH. et al. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2010; 25: 605-612 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1440-1746.2009.06115.x?download=true
361 Lencioni R. New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma. Clin Cancer Res 2013; 19: 1312-1314 https://clincancerres.aacrjournals.org/content/clincanres/19/6/1312.full.pdf
362 Vincenzi B, Di Maio M, Silletta M. et al. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS One 2015; 10: e0133488 https://iris.unito.it/retrieve/handle/2318/1572009/162002/pone.0133488.pdf
363 Finn RS, Qin S, Ikeda M. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894-1905 https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915745?articleTools=true
364 Cheng AL, Kang YK, Chen Z. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34 https://www.sciencedirect.com/science/article/pii/S1470204508702857?via%3Dihub
365 Kudo M, Finn RS, Qin S. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet 2018; 391: 1163-1173
366 Bruix J, Qin S, Merle P. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2017; 389: 56-66
367 Abou-Alfa GK, Meyer T, Cheng AL. et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018; 379: 54-63 https://www.nejm.org/doi/pdf/10.1056/NEJMoa1717002?articleTools=true
368 Zhu AX, Kang YK, Yen CJ. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 282-296
369 Facciorusso A, Tartaglia N, Villani R. et al. Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis. Am J Transl Res 2021; 13 (04) 2379-2387 https://pubmed.ncbi.nlm.nih.gov/34017396/
370 Abou-Alfa GK, Lau G, Kudo M. et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evidence 2022; 1: EVIDoa2100070
371 Llovet JM, Ricci S, Mazzaferro V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 https://www.nejm.org/doi/pdf/10.1056/NEJMoa0708857?articleTools=true
372 Zhu AX, Kang Y, Yen C. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2019; 20: 282-296
373 Cheng A, Qin S, Ikeda M. et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022; 76 (04) 862-873 https://pubmed.ncbi.nlm.nih.gov/34902530/
374 Galle P, Finn R, Qin S. et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22 (07) 991-1001 https://pubmed.ncbi.nlm.nih.gov/34051880/
375 Cainap C, Qin S, Huang WT. et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015; 33: 172-179 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279237/pdf/zlj172.pdf
376 Johnson PJ, Qin S, Park JW. et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31: 3517-3524
377 Zhu AX, Rosmorduc O, Evans TR. et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015; 33: 559-566 http://diposit.ub.edu/dspace/bitstream/2445/117402/1/649304.pdf
378 Cheng AL, Kang YK, Lin DY. et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31: 4067-4075
379 Yau T, Park J, Finn R. et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022; 23 (01) 77-90 https://pubmed.ncbi.nlm.nih.gov/34914889/
380 Marrero JA, Kudo M, Venook AP. et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol 2016; 65: 1140-1147 https://www.journal-of-hepatology.eu/article/S0168-8278(16)30346-4/pdf
381 Ganten TM, Stauber RE, Schott E. et al. Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study. Clin Cancer Res 2017; 23: 5720-5728 https://clincancerres.aacrjournals.org/content/clincanres/23/19/5720.full.pdf
382 Leal CRG, Magalhães C, Barbosa D. et al. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study. Invest New Drugs 2018; 36: 911-918
383 Pressiani T, Boni C, Rimassa L. et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013; 24: 406-411 https://www.annalsofoncology.org/article/S0923-7534(19)36863-2/pdf
384 Ogasawara S, Chiba T, Ooka Y. et al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 2015; 33: 729-739 https://link.springer.com/article/10.1007%2Fs10637-015-0237-3
385 El-Khoueiry A, Meyer T, Cheng A. et al. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial. BMC Cancer 2022; 22 (01) 377 https://pubmed.ncbi.nlm.nih.gov/35397508/
386 Huynh J, Cho M, Kim E. et al. Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function. Ther Adv Med Oncol 2022; 14 https://pubmed.ncbi.nlm.nih.gov/36051472/
387 Kambhampati S, Bauer KE, Bracci PM. et al. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer 2019; 125: 3234-3241 https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.32206?download=true
388 Kudo M, Matilla A, Santoro A. et al. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol 2021; 75 (03) 600-609 https://pubmed.ncbi.nlm.nih.gov/34051329/
389 Scheiner B, Kirstein M, Hucke F. et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther 2019; 49 (10) 1323-1333 https://pubmed.ncbi.nlm.nih.gov/30980420/
390 Spahn S, Roessler D, Pompilia R. et al. Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers (Basel) 2020; 12 (12) https://pubmed.ncbi.nlm.nih.gov/33353145/
391 DʼAlessio A, Fulgenzi C, Nishida N. et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. Hepatology 2022; 76 (04) 1000-1012 https://pubmed.ncbi.nlm.nih.gov/35313048/
392 de Castro T, Jochheim L, Bathon M. et al. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol 2022; 14 https://pubmed.ncbi.nlm.nih.gov/35251317/
393 Vilgrain V, Pereira H, Assenat E. et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017; 18: 1624-1636 https://www.sciencedirect.com/science/article/abs/pii/S1470204517306836
394 Lencioni R, Llovet JM, Han G. et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 2016; 64: 1090-1098 https://www.ncbi.nlm.nih.gov/pubmed/26809111
395 Meyer T, Fox R, Ma YT. et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2: 565-575 https://www.thelancet.com/pdfs/journals/langas/PIIS2468-1253(17)30156-5.pdf
396 Kudo M, Ueshima K, Ikeda M. et al. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer 2022; 11 (04) 354-367 https://pubmed.ncbi.nlm.nih.gov/35978604/
397 Ding X, Sun W, Li W. et al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study. Cancer 2021; 127 (20) 3782-3793 https://pubmed.ncbi.nlm.nih.gov/34237154/
398 Cai M, Huang W, Huang J. et al. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. Front Immunol 2022; 13: 848387 https://pubmed.ncbi.nlm.nih.gov/35300325/
399 Marinelli B, Kim E, DʼAlessio A. et al. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer 2022; 10 (06) https://pubmed.ncbi.nlm.nih.gov/35710293/
400 Fan W, Zhu B, Yue S. et al. Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis. Cancer Med 2023; 12 (01) 61-72 https://pubmed.ncbi.nlm.nih.gov/35698292/
401 Ricke J, Klümpen HJ, Amthauer H. et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 2019; 71: 1164-1174 https://www.journal-of-hepatology.eu/article/S0168-8278(19)30472-6/fulltext
402 Kudo M, Ueshima K, Ikeda M. et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020; 69: 1492-1501 https://www.ncbi.nlm.nih.gov/pubmed/31801872
403 Kudo M, Ikeda M, Ueshima K. et al. Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version). Hepatol Res 2019; 49: 981-989 https://www.ncbi.nlm.nih.gov/pubmed/31231916
404 Kudo M, Ueshima K, Ikeda M. et al. TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC). Journal of Clinical Oncology 2021; 39: 270-270 https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.270
405 Bruix J, Qin S, Merle P. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56-66 https://www.sciencedirect.com/science/article/pii/S0140673616324539?via%3Dihub
406 Finn R, Ryoo B, Merle P. et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2020; 38 (03) 193-202 https://pubmed.ncbi.nlm.nih.gov/31790344/
407 Rao Q, Li M, Xu W. et al. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int 2020; 14 (05) 765-775 https://pubmed.ncbi.nlm.nih.gov/32572818/
408 Parikh N, Marshall A, Betts K. et al. Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. J Comp Eff Res 2021; 10 (05) 343-352 https://pubmed.ncbi.nlm.nih.gov/33442996/
409 He S, Jiang W, Fan K. et al. The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2021; 11: 626984 https://pubmed.ncbi.nlm.nih.gov/33833987/
410 El-Khoueiry AB, Sangro B, Yau T. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389: 2492-2502 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539326/pdf/nihms-1623792.pdf
411 Zhu AX, Finn RS, Edeline J. et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19: 940-952 https://www.ncbi.nlm.nih.gov/pubmed/29875066
412 Kudo M, Finn R, Edeline J. et al. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer 2022; 167: 1-12 https://pubmed.ncbi.nlm.nih.gov/35364421/
413 Finn RS, Ryoo BY, Merle P. et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2020; 38: 193-202 https://www.ncbi.nlm.nih.gov/pubmed/31790344
414 Qin S, Chen Z, Fang W. et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. Journal of Clinical Oncology 2022; 40: 383
415 Yau T, Kang Y, Kim T. et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol 2020; 6 (11) e204564 https://pubmed.ncbi.nlm.nih.gov/33001135/
416 Dinh T, Utria A, Barry K. et al. A framework for fibrolamellar carcinoma research and clinical trials. Nat Rev Gastroenterol Hepatol 2022; 19 (05) 328-342 https://pubmed.ncbi.nlm.nih.gov/35190728/
417 Honeyman J, Simon E, Robine N. et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 2014; 343: 1010-1014 https://pubmed.ncbi.nlm.nih.gov/24578576/
418 Ramai D, Ofosu A, Lai J. et al. Fibrolamellar Hepatocellular Carcinoma: A Population-Based Observational Study. Dig Dis Sci 2021; 66 (01) 308-314 https://pubmed.ncbi.nlm.nih.gov/32052215/
419 Rimassa L, Personeni N, Czauderna C. et al. Systemic treatment of HCC in special populations. J Hepatol 2021; 74 (04) 931-943 https://pubmed.ncbi.nlm.nih.gov/33248171/
420 Wege H, Schulze K, von Felden J. et al. Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas. Eur J Med Genet 2021; 64 (11) 104313 https://pubmed.ncbi.nlm.nih.gov/34418585/
421 Chakrabarti S, Tella S, Kommalapati A. et al. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. J Gastrointest Oncol 2019; 10 (03) 554-561 https://pubmed.ncbi.nlm.nih.gov/31183207/
422 Gras P, Truant S, Boige V. et al. Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma. Case Rep Oncol 2012; 5 (01) 169-172 https://pubmed.ncbi.nlm.nih.gov/22666208/
423 Patt Y, Hassan M, Lozano R. et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003; 21 (03) 421-427 https://pubmed.ncbi.nlm.nih.gov/12560429/
424 Kim A, Gani F, Layman A. et al. Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. Cancer Immunol Res 2019; 7 (05) 805-812 https://pubmed.ncbi.nlm.nih.gov/30902819/
425 Chen K, Popovic A, Hsiehchen D. et al. Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers (Basel) 2022; 14 (21) https://pubmed.ncbi.nlm.nih.gov/36358766/
426 Berger R, Dinstag G, Tirosh O. et al. Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab. J Immunother Cancer 2022; 10 (12) https://pubmed.ncbi.nlm.nih.gov/36600603/
427 De Toni E, Roessler D. Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma. Gut 2020; 69 (11) 2056-2058 https://pubmed.ncbi.nlm.nih.gov/32051207/
428 Kang S, Magliocca J, Sellers M. et al. Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report. Oncol Res Treat 2022; 45 (07) 430-437 https://pubmed.ncbi.nlm.nih.gov/35537414/
429 Nagtegaal I, Odze R, Klimstra D. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76 (02) 182-188 https://pubmed.ncbi.nlm.nih.gov/31433515/
430 Eschrich J, Kobus Z, Geisel D. et al. The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma-State of the Art and Future Perspectives. Cancers (Basel) 2023; 15 (01) https://pubmed.ncbi.nlm.nih.gov/36612297/
431 Gigante E, Paradis V, Ronot M. et al. New insights into the pathophysiology and clinical care of rare primary liver cancers. JHEP Rep 2021; 3 (01) 100174 https://pubmed.ncbi.nlm.nih.gov/33205035/
432 Xue R, Chen L, Zhang C. et al. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes. Cancer Cell 2019; 35 (06) 932-947.e8 https://pubmed.ncbi.nlm.nih.gov/31130341/
433 Gigante E, Hobeika C, Le BailB. et al. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma. Liver Cancer 2022; 11 (05) 460-473 https://pubmed.ncbi.nlm.nih.gov/36158591/
434 Kim E, Yoo C, Kang H. et al. Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma. Liver Int 2021; 41 (06) 1398-1408 https://pubmed.ncbi.nlm.nih.gov/33548073/
435 Kobayashi S, Terashima T, Shiba S. et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci 2018; 109 (08) 2549-2557 https://pubmed.ncbi.nlm.nih.gov/29856900/
436 Rogers J, Bolonesi R, Rashid A. et al. Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. J Gastrointest Oncol 2017; 8 (02) 347-351 https://pubmed.ncbi.nlm.nih.gov/28480073/
437 Trikalinos N, Zhou A, Doyle M. et al. Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience. J Natl Compr Canc Netw 2018; 16 (10) 1193-1199 https://pubmed.ncbi.nlm.nih.gov/30323089/
438 Salimon M, Prieux-Klotz C, Tougeron D. et al. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer 2018; 118 (03) 325-330 https://pubmed.ncbi.nlm.nih.gov/29169182/
439 Bruix J, Takayama T, Mazzaferro V. et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16: 1344-1354 https://www.sciencedirect.com/science/article/pii/S1470204515001989?via%3Dihub
440 Ho W, Zhu Q, Durham J. et al. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. Nat Cancer 2021; 2 (09) 891-903 https://pubmed.ncbi.nlm.nih.gov/34796337/
441 Kaseb A, Hasanov E, Cao H. et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2022; 7 (03) 208-218 https://pubmed.ncbi.nlm.nih.gov/35065057/
442 Marron T, Fiel M, Hamon P. et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2022; 7 (03) 219-229 https://pubmed.ncbi.nlm.nih.gov/35065058/
443 Xia Y, Tang W, Qian X. et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer 2022; 10 (04) https://pubmed.ncbi.nlm.nih.gov/35379737/
444 Katzenstein HM, Krailo MD, Malogolowkin MH. et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Childrenʼs Cancer Group intergroup study. J Clin Oncol 2002; 20: 2789-2797
445 Czauderna P, Mackinlay G, Perilongo G. et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002; 20: 2798-2804 https://www.ncbi.nlm.nih.gov/pubmed/12065556
446 Schmid I, von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. J Hepatocell Carcinoma 2017; 4: 15-21 https://pubmed.ncbi.nlm.nih.gov/28144610/
447 Schmid I, Häberle B, Albert MH. et al. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer 2012; 58: 539-544 https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.23295
448 Schütte K, Tippelt B, Schulz C. et al. Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). Clin Nutr 2015; 34: 1122-1127
449 Huang TH, Hsieh CC, Kuo LM. et al. Malnutrition associated with an increased risk of postoperative complications following hepatectomy in patients with hepatocellular carcinoma. HPB (Oxford) 2019; 21: 1150-1155
450 Arends J, Bachmann P, Baracos V. et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017; 36: 11-48
451 Ciuni R, Biondi A, Grosso G. et al. Nutritional aspects in patient undergoing liver resection. Updates Surg 2011; 63: 249-252 https://link.springer.com/content/pdf/10.1007/s13304-011-0121-4.pdf
452 Cederholm T, Jensen GL, Correia M. et al. GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle 2019; 10: 207-217 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438340/pdf/JCSM-10-207.pdf
453 Fujiwara N, Nakagawa H, Kudo Y. et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 2015; 63: 131-140
454 Badran H, Elsabaawy MM, Ragab A. et al. Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients. Asian Pac J Cancer Prev 2020; 21: 3285-3290 http://journal.waocp.org/article_89349_cc643ce4770cf7eeca5890c5d5c453d5.pdf
455 Kim N, Yu JI, Park HC. et al. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunol Immunother 2021; https://link.springer.com/content/pdf/10.1007/s00262-020-02794-3.pdf
456 Mardian Y, Yano Y, Ratnasari N. et al. "Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study". BMC Gastroenterol 2019; 19: 229 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937974/pdf/12876_2019_Article_1152.pdf
457 Voron T, Tselikas L, Pietrasz D. et al. Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma. Ann Surg 2015; 261: 1173-1183
458 Plauth M, Bernal W, Dasarathy S. et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr 2019; 38: 485-521 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686849/pdf/nihms-1529826.pdf
459 Haun MW, Estel S, Rucker G. et al. Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev 2017; 6: CD011129 http://www.ncbi.nlm.nih.gov/pubmed/28603881
460 Adler K, Schlieper D, Kindgen-Milles D. et al. [Integration of palliative care into intensive care: Systematic review]. Anaesthesist 2017; 66: 660-666 http://www.ncbi.nlm.nih.gov/pubmed/28589374
461 Dalgaard KM, Bergenholtz H, Nielsen ME. et al. Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome. Palliat Support Care 2014; 12: 495-513 http://www.ncbi.nlm.nih.gov/pubmed/24621947
462 Davis MP, Temel JS, Balboni T. et al. A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses. Ann Palliat Med 2015; 4: 99-121 http://www.ncbi.nlm.nih.gov/pubmed/26231807
463 Hui D, Kim YJ, Park JC. et al. Integration of oncology and palliative care: a systematic review. Oncologist 2015; 20: 77-83 http://www.ncbi.nlm.nih.gov/pubmed/25480826
464 Hui D, Meng YC, Bruera S. et al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review. Oncologist 2016; 21: 895-901 http://www.ncbi.nlm.nih.gov/pubmed/27185614
465 Tassinari D, Drudi F, Monterubbianesi MC. et al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature. Rev Recent Clin Trials 2016; 11: 63-71 http://www.ncbi.nlm.nih.gov/pubmed/26464077
466 Gärtner U, Braun GD, Held K. et al. [Physical complaints, stress and quality of life of oncologic patients Effects and patient assessment in inpatient rehabilitation]. Med Klin (Munich) 1996; 91: 501-508
467 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK). Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung. Version 2.2. 2020 https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmedizin/
468 Hamano J, Morita T, Inoue S. et al. Surprise Questions for Survival Prediction in Patients With Advanced Cancer: A Multicenter Prospective Cohort Study. Oncologist 2015; 20: 839-844 http://www.ncbi.nlm.nih.gov/pubmed/26054631
469 Moroni M, Zocchi D, Bolognesi D. et al. The “surprise” question in advanced cancer patients: A prospective study among general practitioners. Palliat Med 2014; 28: 959-964 http://www.ncbi.nlm.nih.gov/pubmed/24662237
470 Murray S, Boyd K. Using the “surprise question” can identify people with advanced heart failure and COPD who would benefit from a palliative care approach. Palliat Med 2011; 25: 382 http://www.ncbi.nlm.nih.gov/pubmed/21610113
471 Moss AH, Lunney JR, Culp S. et al. Prognostic significance of the "surprise" question in cancer patients. J Palliat Med 2010; 13: 837-840 http://www.ncbi.nlm.nih.gov/pubmed/20636154
472 Kremer AE, Beuers U, Oude-Elferink RP. et al. Pathogenesis and treatment of pruritus in cholestasis. Drugs 2008; 68: 2163-2182 http://www.ncbi.nlm.nih.gov/pubmed/18840005
473 Stander S, Zeidler C, Augustin M. et al. S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus – Update – Kurzversion. J Dtsch Dermatol Ges 2017; 15: 860-873 http://www.ncbi.nlm.nih.gov/pubmed/28763608
474 Stander S, Raap U, Weisshaar E. et al. Pathogenesis of pruritus. J Dtsch Dermatol Ges 2011; 9: 456-463 http://www.ncbi.nlm.nih.gov/pubmed/21208378
475 Bachs L, Pares A, Elena M. et al. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 1: 574-576 http://www.ncbi.nlm.nih.gov/pubmed/2564110
476 Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94: 488-493 http://www.ncbi.nlm.nih.gov/pubmed/3275568
477 Terg R, Coronel E, Sorda J. et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37: 717-722 http://www.ncbi.nlm.nih.gov/pubmed/12445410
478 Bergasa NV, Talbot TL, Alling DW. et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102: 544-549 http://www.ncbi.nlm.nih.gov/pubmed/1732125
479 Mayo MJ, Handem I, Saldana S. et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007; 45: 666-674 http://www.ncbi.nlm.nih.gov/pubmed/17326161
480 Lindor KD. Ursodiol for primary sclerosing cholangitis Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-695 http://www.ncbi.nlm.nih.gov/pubmed/9041099
481 Talwalkar JA, Souto E, Jorgensen RA. et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003; 1: 297-302 http://www.ncbi.nlm.nih.gov/pubmed/15017671
482 Zapata R, Sandoval L, Palma J. et al. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy A 12-year experience. Liver Int 2005; 25: 548-554 http://www.ncbi.nlm.nih.gov/pubmed/15910492
483 Lemyze M, Dharancy S, Nevière R. et al. Aerobic capacity in patients with chronic liver disease: Very modest effect of liver transplantation. Presse Med 2010; 39: e174-e81
484 Epstein SK, Freeman RB, Khayat A. et al. Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transpl 2004; 10: 418-424 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.20088?download=true
485 van Ginneken BT, van den Berg-Emons RJ, Kazemier G. et al. Physical fitness, fatigue, and quality of life after liver transplantation. Eur J Appl Physiol 2007; 100: 345-353 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1914221/pdf/421_2007_Article_435.pdf
486 van den Berg-Emons R, van Ginneken B, Wijffels M. et al. Fatigue is a major problem after liver transplantation. Liver Transpl 2006; 12: 928-933 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.20684?download=true
487 van Ginneken BT, van den Berg-Emons HJ, Metselaar HJ. et al. Effects of a rehabilitation programme on daily functioning, participation, health-related quality of life, anxiety and depression in liver transplant recipients. Disabil Rehabil 2010; 32: 2107-2112 https://www.tandfonline.com/doi/abs/10.3109/09638288.2010.482174
488 Schwibbe G. [Changes in quality of life in oncological patients in the course of an inpatient after-care program]. Rehabilitation (Stuttg) 1991; 30: 55-62
489 Fan SY, Eiser C, Ho MC. et al. Health-related quality of life in patients with hepatocellular carcinoma: the mediation effects of illness perceptions and coping. Psychooncology 2013; 22: 1353-1360 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pon.3146?download=true
490 Fan SY, Eiser C, Ho MC. Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroenterol Hepatol 2010; 8: 559-564.e1–10 https://www.sciencedirect.com/science/article/abs/pii/S1542356510002533?via%3Dihub
491 Qiao CX, Zhai XF, Ling CQ. et al. Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma. World J Gastroenterol 2012; 18: 2689-2694 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370007/pdf/WJG-18-2689.pdf
492 Steel JL, Geller DA, Gamblin TC. et al. Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol 2007; 25: 2397-2405
493 Lee HH, Chiu CC, Lin JJ. et al. Impact of preoperative anxiety and depression on quality of life before and after resection of hepatocellular carcinoma. J Affect Disord 2019; 246: 361-367 https://www.sciencedirect.com/science/article/abs/pii/S0165032718318639?via%3Dihub
494 Huang TW, Lin CC. The mediating effects of depression on sleep disturbance and fatigue: symptom clusters in patients with hepatocellular carcinoma. Cancer Nurs 2009; 32: 398-403
495 Ahn MH, Park S, Lee HB. et al. Suicide in cancer patients within the first year of diagnosis. Psychooncology 2015; 24: 601-607 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pon.3705?download=true
496 Chiu CC, Lee KT, Wang JJ. et al. Health-Related Quality of Life before and after Surgical Resection of Hepatocellular Carcinoma: A Prospective Study. Asian Pac J Cancer Prev 2018; 19: 65-72 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844638/pdf/APJCP-19-65.pdf
497 Shun SC, Chen CH, Sheu JC. et al. Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. Oncologist 2012; 17: 732-739 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360913/pdf/onc732.pdf
498 Shun SC, Lai YH, Hung H. et al. The Role of Age in Change in Unmet Supportive Care Needs in Hepatocellular Carcinoma Patients During Transition From Hospital to Home. Cancer Nurs 2017; 40: 245-254
499 Wang ZX, Liu SL, Sun CH. et al. Psychological intervention reduces postembolization pain during hepatic arterial chemoembolization therapy: a complementary approach to drug analgesia. World J Gastroenterol 2008; 14: 931-935 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687062/pdf/WJG-14-931.pdf
500 Sanson-Fisher R, Girgis A, Boyes A. et al. The unmet supportive care needs of patients with cancer Supportive Care Review Group. Cancer 2000; 88: 226-237 https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/%28SICI%291097-0142%2820000101%2988%3A1%3C226%3A%3AAID-CNCR30%3E3.0.CO%3B2-P?download=true
501 Kleeberg UR, Tews JT, Ruprecht T. et al. Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study. Support Care Cancer 2005; 13: 303-310 https://link.springer.com/content/pdf/10.1007/s00520-004-0727-x.pdf
502 Fallowfield L, Jenkins V. Communicating sad, bad, and difficult news in medicine. Lancet 2004; 363: 312-319
503 Ong LM, Visser MR, Lammes FB. et al. Doctor-patient communication and cancer patientsʼ quality of life and satisfaction. Patient Educ Couns 2000; 41: 145-156
504 de Haes H, Teunissen S. Communication in palliative care: a review of recent literature. Curr Opin Oncol 2005; 17: 345-350
505 Fukui S, Ogawa K, Ohtsuka M. et al. A randomized study assessing the efficacy of communication skill training on patientsʼ psychologic distress and coping: nursesʼ communication with patients just after being diagnosed with cancer. Cancer 2008; 113: 1462-1470 https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.23710?download=true
506 Razavi D, Merckaert I, Marchal S. et al. How to optimize physiciansʼ communication skills in cancer care: results of a randomized study assessing the usefulness of posttraining consolidation workshops. J Clin Oncol 2003; 21: 3141-3149
507 Lienard A, Merckaert I, Libert Y. et al. Factors that influence cancer patientsʼ and relativesʼ anxiety following a three-person medical consultation: impact of a communication skills training program for physicians. Psychooncology 2008; 17: 488-496 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pon.1262?download=true
508 Edwards A, Elwyn G. Inside the black box of shared decision making: distinguishing between the process of involvement and who makes the decision. Health Expect 2006; 9: 307-320 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5060371/pdf/HEX-9-307.pdf
509 Butow P, Juraskova I, Chang S. et al. Shared decision making coding systems: how do they compare in the oncology context?. Patient Educ Couns 2010; 78: 261-268
510 Gordon EJ, Bergeron A, McNatt G. et al. Are informed consent forms for organ transplantation and donation too difficult to read?. Clin Transplant 2012; 26: 275-283 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1399-0012.2011.01480.x?download=true
511 Volk ML, Tocco RS, Pelletier SJ. et al. Patient decision making about organ quality in liver transplantation. Liver Transpl 2011; 17: 1387-1393 https://deepblue.lib.umich.edu/bitstream/handle/2027.42/88081/22437_ftp.pdf?sequence=1
512 Rodrigue JR, Hanto DW, Curry MP. Patientsʼ expectations and success criteria for liver transplantation. Liver Transpl 2011; 17: 1309-1317 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.22355?download=true
513 Butow PN, Tattersall MH, Goldstein D. Communication with cancer patients in culturally diverse societies. Ann N Y Acad Sci 1997; 809: 317-329 https://nyaspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1749-6632.1997.tb48095.x?download=true
514 Dowsett SM, Saul JL, Butow PN. et al. Communication styles in the cancer consultation: preferences for a patient-centred approach. Psychooncology 2000; 9: 147-156 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/%28SICI%291099-1611%28200003/04%299%3A2%3C147%3A%3AAID-PON443%3E3.0.CO%3B2-X?download=true
515 Epstein RM. Making communication research matter: what do patients notice, what do patients want, and what do patients need?. Patient Educ Couns 2006; 60: 272-278
516 Zachariae R, Pedersen CG, Jensen AB. et al. Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease. Br J Cancer 2003; 88: 658-665 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376357/pdf/88-6600798a.pdf
517 Strasser F, Palmer JL, Willey J. et al. Impact of physician sitting versus standing during inpatient oncology consultations: patientsʼ preference and perception of compassion and duration A randomized controlled trial. J Pain Symptom Manage 2005; 29: 489-497
518 Fogarty LA, Curbow BA, Wingard JR. et al. Can 40 seconds of compassion reduce patient anxiety?. J Clin Oncol 1999; 17: 371-379
519 Atchison EA, Gridley G, Carreon JD. et al. Risk of cancer in a large cohort of US veterans with diabetes. Int J Cancer 2011; 128: 635-643 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.25362?download=true
520 de Valle MB, Björnsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int 2012; 32: 441-448 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1478-3231.2011.02614.x?download=true
521 El-Serag HB, Engels EA, Landgren O. et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of US veterans. Hepatology 2009; 49: 116-123 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.22606?download=true
522 Huang Y, You L, Xie W. et al. Smoking and risk of cholangiocarcinoma: a systematic review and meta-analysis. Oncotarget 2017; 8: 100570-100581 https://www.oncotarget.com/article/20141/pdf/
523 Jing W, Jin G, Zhou X. et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev 2012; 21: 24-31
524 Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57: 69-76 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804834/pdf/nihms363811.pdf
525 Wongjarupong N, Assavapongpaiboon B, Susantitaphong P. et al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2017; 17: 149 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721586/pdf/12876_2017_Article_696.pdf
526 Park JY, Hong SP, Kim YJ. et al. Long-term follow up of gallbladder polyps. J Gastroenterol Hepatol 2009; 24: 219-222 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1440-1746.2008.05689.x?download=true
527 Nagaraja V, Eslick GD. Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer. Aliment Pharmacol Ther 2014; 39: 745-750 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.12655?download=true
528 Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014; 383: 2168-2179 https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(13)61903-0.pdf
529 Rizvi S, Khan SA, Hallemeier CL. et al. Cholangiocarcinoma – evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 2018; 15: 95-111
530 Valle JW, Borbath I, Khan SA. et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v28-v37 https://pubmed.ncbi.nlm.nih.gov/27664259/
531 Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013; 145: 1215-1229 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862291/pdf/nihms535439.pdf
532 Kamsa-ard S, Kamsa-ard S, Luvira V. et al. Risk Factors for Cholangiocarcinoma in Thailand: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev 2018; 19: 605-614 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980830/pdf/APJCP-19-605.pdf
533 Qian MB, Utzinger J, Keiser J. et al. Clonorchiasis. Lancet 2016; 387: 800-810
534 Qian MB, Zhou XN. Global burden of cancers attributable to liver flukes. Lancet Glob Health 2017; 5: e139
535 You MS, Lee SH, Kang J. et al. Natural Course and Risk of Cholangiocarcinoma in Patients with Recurrent Pyogenic Cholangitis: A Retrospective Cohort Study. Gut Liver 2019; 13: 373-379 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529165/pdf/gnl-13-373.pdf
536 Ten HoveA, de Meijer VE, Hulscher JBF. et al. Meta-analysis of risk of developing malignancy in congenital choledochal malformation. Br J Surg 2018; 105: 482-490 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900735/pdf/BJS-105-482.pdf
537 Fahrner R, Dennler SG, Inderbitzin D. Risk of malignancy in Caroli disease and syndrome: A systematic review. World J Gastroenterol 2020; 26: 4718-4728 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445861/pdf/WJG-26-4718.pdf
538 Claessen MM, Vleggaar FP, Tytgat KM. et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50: 158-164
539 Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011; 54: 173-184 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.24351?download=true
540 McGee EE, Jackson SS, Petrick JL. et al. Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. J Natl Cancer Inst 2019; 111: 1263-1278 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910180/pdf/djz103.pdf
541 Clements O, Eliahoo J, Kim JU. et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J Hepatol 2020; 72: 95-103
542 Schmidt MA, Marcano-Bonilla L, Roberts LR. Gallbladder cancer: epidemiology and genetic risk associations. Chin Clin Oncol 2019; 8: 31 http://cco.amegroups.com/article/view/28517/25064
543 Rawla P, Sunkara T, Thandra KC. et al. Epidemiology of gallbladder cancer. Clin Exp Hepatol 2019; 5: 93-102 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728871/pdf/CEH-5-36699.pdf
544 Kratzer W, Schmid A, Akinli AS. et al. [Gallbladder polyps: prevalence and risk factors]. Ultraschall in Med 2011; 32 (Suppl. 01) S68-S73 https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0029-1245265.pdf
545 Schnelldorfer T. Porcelain gallbladder: a benign process or concern for malignancy?. J Gastrointest Surg 2013; 17: 1161-1168 https://link.springer.com/content/pdf/10.1007/s11605-013-2170-0.pdf
546 DesJardins H, Duy L, Scheirey C. et al. Porcelain Gallbladder: Is Observation a Safe Option in Select Populations?. J Am Coll Surg 2018; 226: 1064-1069 https://www.sciencedirect.com/science/article/abs/pii/S1072751518301571?via%3Dihub
547 Patel S, Roa JC, Tapia O. et al. Hyalinizing cholecystitis and associated carcinomas: clinicopathologic analysis of a distinctive variant of cholecystitis with porcelain-like features and accompanying diagnostically challenging carcinomas. Am J Surg Pathol 2011; 35: 1104-1113
548 Gutt C, Jenssen C, Barreiros AP. et al. [Updated S3-Guideline for Prophylaxis, Diagnosis and Treatment of Gallstones German Society for Digestive and Metabolic Diseases (DGVS) and German Society for Surgery of the Alimentary Tract (DGAV) – AWMF Registry 021/008]. Z Gastroenterol 2018; 56: 912-966 https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0644-2972.pdf
549 Eaton JE, Thackeray EW, Lindor KD. Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol 2012; 107: 431-439
550 [Practice guideline autoimmune liver diseases – AWMF-Reg No 021-27]. Z Gastroenterol 2017; 55: 1135-1226
551 Wiles R, Thoeni RF, Barbu ST. et al. Management and follow-up of gallbladder polyps: Joint guidelines between the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), European Association for Endoscopic Surgery and other Interventional Techniques (EAES), International Society of Digestive Surgery - European Federation (EFISDS) and European Society of Gastrointestinal Endoscopy (ESGE). Eur Radiol 2017; 27: 3856-3866 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544788/pdf/330_2017_Article_4742.pdf
552 Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World J Gastroenterol 2019; 25: 659-671 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378537/pdf/WJG-25-659.pdf
553 Charatcharoenwitthaya P, Enders FB, Halling KC. et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008; 48: 1106-1117 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.22441?download=true
554 Naitoh I, Nakazawa T, Kato A. et al. Predictive factors for positive diagnosis of malignant biliary strictures by transpapillary brush cytology and forceps biopsy. J Dig Dis 2016; 17: 44-51
555 Navaneethan U, Njei B, Lourdusamy V. et al. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc 2015; 81: 168-176 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824293/pdf/nihms773255.pdf
556 Klimstra DS LA. Tumors of the gallbladder and extrahepatic bile ducts. In: WHO Classification of Tumours Editorial Board WHO-Classification of Tumours (5th ed.) Digestive System Tumours. Lyon: International Agency for Research on Cancer; 2019: 265-294
557 Moeini A, Sia D, Zhang Z. et al. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol 2017; 66: 952-961
558 Paradis VSP. Other tumours of the digestive system. In: WHO Classification of Tumours Editorial Board WHO-Classification of Tumours (5th ed.) Digestive System Tumours. Lyon: International Agency for Research on Cancer; 2019: 499-510
559 C W. TNM-Klassifikation maligner Tumoren. 8 Aufl.. Weinheim: Wiley-VCH; 2020
560 Wagner GHP. Organspezifische Tumordokumentation – Prinzipien und Verschlüsselungsanweisungen für Klinik und Praxis. Frankfurt (Main).: Online-version: deutsche Krebsgesellschaft; 1995
561 Khuntikeo N, Chamadol N, Yongvanit P. et al. Cohort profile: cholangiocarcinoma screening and care program (CASCAP). BMC Cancer 2015; 15: 459 https://www.ncbi.nlm.nih.gov/pubmed/26054405
562 Li R, Zhang X, Ma KS. et al. Dynamic enhancing vascular pattern of intrahepatic peripheral cholangiocarcinoma on contrast-enhanced ultrasound: the influence of chronic hepatitis and cirrhosis. Abdom Imaging 2013; 38: 112-119 https://link.springer.com/content/pdf/10.1007%2Fs00261-012-9854-x.pdf
563 Xu HX, Chen LD, Liu LN. et al. Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination. Br J Radiol 2012; 85: 1029-1037 https://www.ncbi.nlm.nih.gov/pubmed/22374276
564 Wildner D, Bernatik T, Greis C. et al. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients – early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall in Med 2015; 36: 132-139 https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0034-1399147.pdf
565 Bach AM, Hann LE, Brown KT. et al. Portal vein evaluation with US: comparison to angiography combined with CT arterial portography. Radiology 1996; 201: 149-154 https://www.ncbi.nlm.nih.gov/pubmed/8816536
566 Wennmacker SZ, Lamberts MP, Di Martino M. et al. Transabdominal ultrasound and endoscopic ultrasound for diagnosis of gallbladder polyps. Cochrane Database Syst Rev 2018; 8: CD012233 https://www.ncbi.nlm.nih.gov/pubmed/30109701
567 Zhang Y, Uchida M, Abe T. et al. Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI. J Comput Assist Tomogr 1999; 23: 670-677 https://www.ncbi.nlm.nih.gov/pubmed/10524843
568 Johnson PT, Fishman EK. Routine use of precontrast and delayed acquisitions in abdominal CT: time for change. Abdom Imaging 2013; 38: 215-223 https://www.ncbi.nlm.nih.gov/pubmed/23132390
569 Fabrega-Foster K, Ghasabeh MA, Pawlik TM. et al. Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017; 6: 67-78 https://www.ncbi.nlm.nih.gov/pubmed/28503554
570 Valls C, Guma A, Puig I. et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging 2000; 25: 490-496 https://www.ncbi.nlm.nih.gov/pubmed/10931983
571 Kim JH, Won HJ, Shin YM. et al. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. Am J Roentgenol 2011; 196: W205-W209 https://www.ajronline.org/doi/pdfplus/10.2214/AJR.10.4937
572 Bridgewater J, Galle PR, Khan SA. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014; 60: 1268-1289 https://www.ncbi.nlm.nih.gov/pubmed/24681130
573 Jhaveri KS, Hosseini-Nik H. MRI of cholangiocarcinoma. J Magn Reson Imaging 2015; 42: 1165-1179 https://www.ncbi.nlm.nih.gov/pubmed/25447417
574 Murakami T, Nakamura H, Tsuda K. et al. Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study. J Magn Reson Imaging 1995; 5: 165-170 https://www.ncbi.nlm.nih.gov/pubmed/7766977
575 Hamrick-Turner J, Abbitt PL, Ros PR. Intrahepatic cholangiocarcinoma: MR appearance. Am J Roentgenol 1992; 158: 77-79 https://www.ncbi.nlm.nih.gov/pubmed/1309221
576 Fan ZM, Yamashita Y, Harada M. et al. Intrahepatic cholangiocarcinoma: spin-echo and contrast-enhanced dynamic MR imaging. Am J Roentgenol 1993; 161: 313-317 https://www.ncbi.nlm.nih.gov/pubmed/8392787
577 https://www.ncbi.nlm.nih.gov/pubmed/24559750
578 Chung YE, Kim MJ, Park YN. et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 2009; 29: 683-700 https://www.ncbi.nlm.nih.gov/pubmed/19448110
579 Park HJ, Kim YK, Park MJ. et al. Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 2013; 38: 793-801 https://www.ncbi.nlm.nih.gov/pubmed/22829097
580 Fattach HE, Dohan A, Guerrache Y. et al. Intrahepatic and hilar mass-forming cholangiocarcinoma: Qualitative and quantitative evaluation with diffusion-weighted MR imaging. Eur J Radiol 2015; 84: 1444-1451 https://www.ncbi.nlm.nih.gov/pubmed/26022518
581 Navaneethan U, Njei B, Venkatesh PG. et al. Endoscopic ultrasound in the diagnosis of cholangiocarcinoma as the etiology of biliary strictures: a systematic review and meta-analysis. Gastroenterol Rep (Oxf) 2015; 3: 209-215 https://www.ncbi.nlm.nih.gov/pubmed/25169922
582 Pahade JK, Juice D, Staib L. et al. Is there an added value of a hepatobiliary phase with gadoxetate disodium following conventional MRI with an extracellular gadolinium agent in a single imaging session for detection of primary hepatic malignancies?. Abdom Radiol (NY) 2016; 41: 1270-1284 https://link.springer.com/content/pdf/10.1007%2Fs00261-016-0635-9.pdf
583 Park HJ, Kim SH, Jang KM. et al. The role of diffusion-weighted MR imaging for differentiating benign from malignant bile duct strictures. Eur Radiol 2014; 24: 947-958 https://www.ncbi.nlm.nih.gov/pubmed/24487774
584 Lee J, Kim SH, Kang TW. et al. Mass-forming Intrahepatic Cholangiocarcinoma: Diffusion-weighted Imaging as a Preoperative Prognostic Marker. Radiology 2016; 281: 119-128 https://www.ncbi.nlm.nih.gov/pubmed/27115053
585 Rupp C, Hippchen T, Bruckner T. et al. Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut 2019; 68: 2170-2178 https://www.ncbi.nlm.nih.gov/pubmed/30910856
586 Zhang H, Zhu J, Ke F. et al. Radiological Imaging for Assessing the Respectability of Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Biomed Res Int 2015; 2015: 497942 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569758/pdf/BMRI2015-497942.pdf
587 Lamarca A, Barriuso J, Chander A. et al. (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. J Hepatol 2019; 71: 115-129
588 Feng ST, Wu L, Cai H. et al. Cholangiocarcinoma: spectrum of appearances on Gd-EOB-DTPA-enhanced MR imaging and the effect of biliary function on signal intensity. BMC Cancer 2015; 15: 38 https://www.ncbi.nlm.nih.gov/pubmed/25655565
589 Kim SH, Lee CH, Kim BH. et al. Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 2012; 36: 704-709 https://www.ncbi.nlm.nih.gov/pubmed/23192208
590 Lamarca A, Barriuso J, Chander A. et al. J Hepatol 2019; 71 (01) 115-129 https://pubmed.ncbi.nlm.nih.gov/30797051/
591 Kiefer LS, Sekler J, Gückel B. et al. Impact of 18F-FDG-PET/CT on Clinical Management in Patients with Cholangiocellular Carcinoma. BJR|Open 2021; 3: 20210008
592 De Moura DTH, Moura EGH, Bernardo WM. et al. Endoscopic retrograde cholangiopancreatography versus endoscopic ultrasound for tissue diagnosis of malignant biliary stricture: Systematic review and meta-analysis. Endosc Ultrasound 2018; 7: 10-19 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838722/pdf/EUS-7-10.pdf
593 Heimbach JK, Sanchez W, Rosen CB. et al. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford) 2011; 13: 356-360 https://www.ncbi.nlm.nih.gov/pubmed/21492336
594 El Chafic AH, Dewitt J, Leblanc JK. et al. Impact of preoperative endoscopic ultrasound-guided fine needle aspiration on postoperative recurrence and survival in cholangiocarcinoma patients. Endoscopy 2013; 45: 883-889 https://www.ncbi.nlm.nih.gov/pubmed/24165813
595 Korc P, Sherman S. ERCP tissue sampling. Gastrointest Endosc 2016; 84: 557-571 https://www.ncbi.nlm.nih.gov/pubmed/27156656
596 Fogel EL, deBellis M, McHenry L. et al. Effectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: a prospective study. Gastrointest Endosc 2006; 63: 71-77 https://www.ncbi.nlm.nih.gov/pubmed/16377319
597 Shieh FK, Luong-Player A, Khara HS. et al. Improved endoscopic retrograde cholangiopancreatography brush increases diagnostic yield of malignant biliary strictures. World J Gastrointest Endosc 2014; 6: 312-317 https://www.ncbi.nlm.nih.gov/pubmed/25031790
598 Glasbrenner B, Ardan M, Boeck W. et al. Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography. Endoscopy 1999; 31: 712-717 https://www.ncbi.nlm.nih.gov/pubmed/10604612
599 Macken E, Drijkoningen M, Van Aken E. et al. Brush cytology of ductal strictures during ERCP. Acta Gastroenterol Belg 2000; 63: 254-259 https://www.ncbi.nlm.nih.gov/pubmed/11189981
600 Mansfield JC, Griffin SM, Wadehra V. et al. A prospective evaluation of cytology from biliary strictures. Gut 1997; 40: 671-677 https://www.ncbi.nlm.nih.gov/pubmed/9203949
601 Trikudanathan G, Navaneethan U, Njei B. et al. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014; 79: 783-789 https://www.ncbi.nlm.nih.gov/pubmed/24140129
602 Draganov PV, Chauhan S, Wagh MS. et al. Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study. Gastrointest Endosc 2012; 75: 347-353 https://www.ncbi.nlm.nih.gov/pubmed/22248602
603 Sugiyama M, Atomi Y, Wada N. et al. Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary strictures: a prospective comparative study with bile and brush cytology. Am J Gastroenterol 1996; 91: 465-467 https://www.ncbi.nlm.nih.gov/pubmed/8633492
604 Jailwala J, Fogel EL, Sherman S. et al. Triple-tissue sampling at ERCP in malignant biliary obstruction. Gastrointest Endosc 2000; 51: 383-390 https://www.ncbi.nlm.nih.gov/pubmed/10744806
605 Hartman DJ, Slivka A, Giusto DA. et al. Tissue yield and diagnostic efficacy of fluoroscopic and cholangioscopic techniques to assess indeterminate biliary strictures. Clin Gastroenterol Hepatol 2012; 10: 1042-1046 https://www.ncbi.nlm.nih.gov/pubmed/22677575
606 Pugliese V, Conio M, Nicolo G. et al. Endoscopic retrograde forceps biopsy and brush cytology of biliary strictures: a prospective study. Gastrointest Endosc 1995; 42: 520-526 https://www.ncbi.nlm.nih.gov/pubmed/8674921
607 Kitajima Y, Ohara H, Nakazawa T. et al. Usefulness of transpapillary bile duct brushing cytology and forceps biopsy for improved diagnosis in patients with biliary strictures. J Gastroenterol Hepatol 2007; 22: 1615-1620 https://www.ncbi.nlm.nih.gov/pubmed/17573833
608 Navaneethan U, Hasan MK, Lourdusamy V. et al. Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review. Gastrointest Endosc 2015; 82: 608-614.e2 https://www.ncbi.nlm.nih.gov/pubmed/26071061
609 Gerges C, Beyna T, Tang RSY. et al. Digital single-operator peroral cholangioscopy-guided biopsy versus ERCP-guided brushing for indeterminate biliary strictures: a prospective, randomized multicenter trial (with video). Gastrointest Endosc 2019; https://www.ncbi.nlm.nih.gov/pubmed/31778656
610 Aabakken L, Karlsen TH, Albert J. et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy 2017; 49: 588-608 https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0043-107029.pdf
611 Bagante F, Spolverato G, Weiss M. et al. Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System. J Gastrointest Surg 2018; 22: 52-59 https://link.springer.com/content/pdf/10.1007/s11605-017-3426-x.pdf
612 Bagante F, Spolverato G, Weiss M. et al. Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Peri-Operative Outcomes. World J Surg 2018; 42: 2551-2560 https://link.springer.com/content/pdf/10.1007/s00268-017-4453-1.pdf
613 Ebata T, Mizuno T, Yokoyama Y. et al. Surgical resection for Bismuth type IV perihilar cholangiocarcinoma. Br J Surg 2018; 105: 829-838 https://bjssjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bjs.10556?download=true
614 El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic Cholangiocarcinoma. Surg Oncol Clin N Am 2019; 28: 587-599 https://www.sciencedirect.com/science/article/abs/pii/S1055320719300444?via%3Dihub
615 Lang H, Sotiropoulos GC, Sgourakis G. et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 2009; 208: 218-228
616 Schnitzbauer AA, Eberhard J, Bartsch F. et al. The MEGNA Score and Preoperative Anemia are Major Prognostic Factors After Resection in the German Intrahepatic Cholangiocarcinoma Cohort. Ann Surg Oncol 2020; 27: 1147-1155 https://link.springer.com/content/pdf/10.1245/s10434-019-07968-7.pdf
617 Zhang XF, Bagante F, Chakedis J. et al. Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy. J Gastrointest Surg 2017; 21: 1841-1850 https://link.springer.com/content/pdf/10.1007/s11605-017-3499-6.pdf
618 Bartsch F, Tripke V, Baumgart J. et al. Extended resection of intrahepatic cholangiocarcinoma: A retrospective single-center cohort study. Int J Surg 2019; 67: 62-69 https://www.sciencedirect.com/science/article/abs/pii/S1743919119301116?via%3Dihub
619 Mizuno T, Ebata T, Nagino M. Advanced hilar cholangiocarcinoma: An aggressive surgical approach for the treatment of advanced hilar cholangiocarcinoma: Perioperative management, extended procedures, and multidisciplinary approaches. Surg Oncol 2020; 33: 201-206 https://www.sciencedirect.com/science/article/abs/pii/S0960740419302439?via%3Dihub
620 Rassam F, Roos E, van Lienden KP. et al. Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience. Langenbecks Arch Surg 2018; 403: 289-307 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986829/pdf/423_2018_Article_1649.pdf
621 Primrose JN, Fox RP, Palmer DH. et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019; 20: 663-673 https://www.sciencedirect.com/science/article/abs/pii/S147020451830915X?via%3Dihub
622 Le RoyB, Gelli M, Pittau G. et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg 2018; 105: 839-847 https://bjssjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bjs.10641?download=true
623 Chang Y, Li Q, Wu Q. et al. Impact of surgical strategies on the survival of gallbladder cancer patients: analysis of 715 cases. World J Surg Oncol 2020; 18: 142 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320575/pdf/12957_2020_Article_1915.pdf
624 Coimbra FJF, Torres OJM, Alikhanov R. et al. BRAZILIAN CONSENSUS ON INCIDENTAL GALLBLADDER CARCINOMA. Arq Bras Cir Dig 2020; 33: e1496 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357549/pdf/0102-6720-abcd-33-01-e1496.pdf
625 Sikora SS, Singh RK. Surgical strategies in patients with gallbladder cancer: nihilism to optimism. J Surg Oncol 2006; 93: 670-681 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jso.20535?download=true
626 Søreide K, Guest RV, Harrison EM. et al. Systematic review of management of incidental gallbladder cancer after cholecystectomy. Br J Surg 2019; 106: 32-45 https://bjssjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bjs.11035?download=true
627 Benson AB, Abrams TA, Ben-Josef E. et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009; 7: 350-391 https://jnccn.org/downloadpdf/journals/jnccn/7/4/article-p350.pdf
628 Yuza K, Sakata J, Prasoon P. et al. Long-term outcomes of surgical resection for T1b gallbladder cancer: an institutional evaluation. BMC Cancer 2020; 20: 20 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945689/pdf/12885_2019_Article_6507.pdf
629 Lee SE, Jang JY, Kim SW. et al. Surgical strategy for T1 gallbladder cancer: a nationwide multicenter survey in South Korea. Ann Surg Oncol 2014; 21: 3654-3660 https://link.springer.com/content/pdf/10.1245/s10434-014-3527-7.pdf
630 Bartsch F, Paschold M, Baumgart J. et al. Surgical Resection for Recurrent Intrahepatic Cholangiocarcinoma. World J Surg 2019; 43: 1105-1116 https://link.springer.com/content/pdf/10.1007/s00268-018-04876-x.pdf
631 Spolverato G, Kim Y, Alexandrescu S. et al. Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection. Ann Surg Oncol 2016; 23: 235-243 https://link.springer.com/content/pdf/10.1245/s10434-015-4642-9.pdf
632 Seidensticker R, Seidensticker M, Doegen K. et al. Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma. Gastroenterol Res Pract 2016; 2016: 8732521 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758109/pdf/GRP2016-8732521.pdf
633 Xu C, Li L, Xu W. et al. Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results. Int J Hyperthermia 2019; 36: 351-358 https://www.tandfonline.com/doi/pdf/10.1080/02656736.2019.1571247?needAccess=true
634 Zhang SJ, Hu P, Wang N. et al. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 2013; 20: 3596-3602 https://link.springer.com/content/pdf/10.1245/s10434-013-3035-1.pdf
635 Amini N, Ejaz A, Spolverato G. et al. Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol 2014; 110: 163-170 https://www.ncbi.nlm.nih.gov/pubmed/24676600
636 Butros SR, Shenoy-Bhangle A, Mueller PR. et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: feasability, local tumor control, and long-term outcome. Clin Imaging 2014; 38: 490-494 https://www.clinicalimaging.org/article/S0899-7071(14)00040-0/fulltext
637 Fu Y, Yang W, Wu W. et al. Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2012; 23: 642-649 https://www.jvir.org/article/S1051-0443(12)00208-4/fulltext
638 Han K, Ko HK, Kim KW. et al. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol 2015; 26: 943-948 https://www.jvir.org/article/S1051-0443(15)00250-X/fulltext
639 Kolarich AR, Shah JL, George TJ. et al. Non-surgical management of patients with intrahepatic cholangiocarcinoma in the United States, 2004-2015: an NCDB analysis. J Gastrointest Oncol 2018; 9: 536-545 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006029/pdf/jgo-09-03-536.pdf
640 Takahashi EA, Kinsman KA, Schmit GD. et al. Thermal ablation of intrahepatic cholangiocarcinoma: Safety, efficacy, and factors affecting local tumor progression. Abdom Radiol (NY) 2018; 43: 3487-3492 https://link.springer.com/content/pdf/10.1007/s00261-018-1656-3.pdf
641 Kim JH, Won HJ, Shin YM. et al. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol 2011; 80: e221-e225 https://www.ejradiology.com/article/S0720-048X(10)00476-6/fulltext
642 Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl 2018; 24: 294-303
643 Facciuto ME, Singh MK, Lubezky N. et al. Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation. Transplantation 2015; 99: 151-157
644 Vilchez V, Shah MB, Daily MF. et al. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB (Oxford) 2016; 18: 29-34 https://www.hpbonline.org/article/S1365-182X(15)00002-7/pdf
645 Sapisochin G, de Lope CR, Gastaca M. et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. Ann Surg 2014; 259: 944-952
646 Sapisochin G, Facciuto M, Rubbia-Brandt L. et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology 2016; 64: 1178-1188
647 Lunsford KE, Javle M, Heyne K. et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol 2018; 3: 337-348 https://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30045-1/fulltext
648 Becker NS, Rodriguez JA, Barshes NR. et al. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 2008; 12: 117-122 https://link.springer.com/content/pdf/10.1007/s11605-007-0335-4.pdf
649 Darwish MuradS, Kim WR, Harnois DM. et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143: 88-98.e3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846443/pdf/nihms507180.pdf
650 Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford) 2008; 10: 186-189 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504373/pdf/MHPB10-186.pdf
651 Gulamhusein AF, Sanchez W. Liver transplantation in the management of perihilar cholangiocarcinoma. Hepat Oncol 2015; 2: 409-421 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095165/pdf/hep-02-409.pdf
652 Ethun CG, Lopez-Aguiar AG, Anderson DJ. et al. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. Ann Surg 2018; 267: 797-805 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002861/pdf/nihms955692.pdf
653 Mantel HT, Westerkamp AC, Adam R. et al. Strict Selection Alone of Patients Undergoing Liver Transplantation for Hilar Cholangiocarcinoma Is Associated with Improved Survival. PLoS One 2016; 11: e0156127 https://air.unimi.it/retrieve/handle/2434/465540/799026/journal.pone.0156127.PDF
654 Weber SM, Ribero D, OʼReilly EM. et al. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford) 2015; 17: 669-680
655 NCCN Guidelines® for Hepatobiliary Cancers Version 3. 2019
656 Ray CE, Edwards A, Smith MT. et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2013; 24: 1218-1226
657 Koch C, Franzke C, Bechstein WO. et al. Poor Prognosis of Advanced Cholangiocarcinoma: Real-World Data from a Tertiary Referral Center. Digestion 2019; 1-8
658 Gusani NJ, Balaa FK, Steel JL. et al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 2008; 12: 129-137 https://link.springer.com/content/pdf/10.1007/s11605-007-0312-y.pdf
659 Boehm LM, Jayakrishnan TT, Miura JT. et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 2015; 111: 213-220 https://onlinelibrary.wiley.com/doi/full/10.1002/jso.23781
660 Kiefer MV, Albert M, McNally M. et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 2011; 117: 1498-1505 https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.25625
661 Vogl TJ, Naguib NN, Nour-Eldin NE. et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. Int J Cancer 2012; 131: 733-740 https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.26407
662 Cucchetti A, Cappelli A, Mosconi C. et al. Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: A meta-regression study. Liver Int 2017; 37: 1056-1064 https://onlinelibrary.wiley.com/doi/full/10.1111/liv.13382
663 Gangi A, Shah J, Hatfield N. et al. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study. J Vasc Interv Radiol 2018; 29: 1101-1108 ttps://www.sciencedirect.com/science/article/pii/S1051044318310868?via%3Dihub
664 Manceau V, Palard X, Rolland Y. et al. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and (90)Y-loaded glass microsphere selective internal radiation therapy. Eur J Nucl Med Mol Imaging 2018; 45: 1731-1741 https://link.springer.com/content/pdf/10.1007%2Fs00259-018-3990-7.pdf
665 Reimer P, Virarkar MK, Binnenhei M. et al. Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-Naïve Patients. Cardiovasc Intervent Radiol 2018; 41: 744-752 https://link.springer.com/content/pdf/10.1007/s00270-017-1871-2.pdf
666 Yang L, Shan J, Shan L. et al. Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Oncol 2015; 6: 570-588 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570915/pdf/jgo-06-05-570.pdf
667 Zhen Y, Liu B, Chang Z. et al. A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma. Onco Targets Ther 2019; 12: 4489-4498 https://pubmed.ncbi.nlm.nih.gov/31239717/
668 Mosconi C, Solaini L, Vara G. et al. Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis. Cardiovasc Intervent Radiol 2021; 44 (05) 728-738 https://pubmed.ncbi.nlm.nih.gov/33709272/
669 Hyder O, Marsh JW, Salem R. et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol 2013; 20: 3779-3786 https://link.springer.com/content/pdf/10.1245/s10434-013-3127-y.pdf
670 Marquardt S, Kirstein MM, Brüning R. et al. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol 2019; 29: 1882-1892 https://link.springer.com/content/pdf/10.1007/s00330-018-5729-z.pdf
671 Edeline J, Touchefeu Y, Guiu B. et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol 2019; 6: 51-59 https://jamanetwork.com/journals/jamaoncology/articlepdf/2753557/jamaoncology_edeline_2019_oi_190074.pdf
672 Konstantinidis IT, Groot KoerkampB, Do RK. et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 2016; 122: 758-765 https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.29824?download=true
673 Al-Adra DP, Gill RS, Axford SJ. et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 2015; 41: 120-127
674 Wronka KM, Grąt M, Stypułkowski J. et al. Relevance of Preoperative Hyperbilirubinemia in Patients Undergoing Hepatobiliary Resection for Hilar Cholangiocarcinoma. J Clin Med 2019; 8 https://res.mdpi.com/d_attachment/jcm/jcm-08-00458/article_deploy/jcm-08-00458.pdf
675 Al Mahjoub A, Menahem B, Fohlen A. et al. Preoperative Biliary Drainage in Patients with Resectable Perihilar Cholangiocarcinoma: Is Percutaneous Transhepatic Biliary Drainage Safer and More Effective than Endoscopic Biliary Drainage?. A Meta-Analysis. J Vasc Interv Radiol 2017; 28: 576-582
676 Hameed A, Pang T, Chiou J. et al. Percutaneous vs endoscopic pre-operative biliary drainage in hilar cholangiocarcinoma – a systematic review and meta-analysis. HPB (Oxford) 2016; 18: 400-410 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857062/pdf/main.pdf
677 Coelen RJS, Roos E, Wiggers JK. et al. Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol 2018; 3: 681-690 https://www.sciencedirect.com/science/article/abs/pii/S2468125318302346?via%3Dihub
678 Ba Y, Yue P, Leung JW. et al. Percutaneous transhepatic biliary drainage may be the preferred preoperative drainage method in hilar cholangiocarcinoma. Endosc Int Open 2020; 8: E203-E210 https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0990-9114.pdf
679 Maeda T, Ebata T, Yokoyama Y. et al. Preoperative course of patients undergoing endoscopic nasobiliary drainage during the management of resectable perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2019; 26: 341-347 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jhbp.640?download=true
680 Nakai Y, Yamamoto R, Matsuyama M. et al. Multicenter study of endoscopic preoperative biliary drainage for malignant hilar biliary obstruction: E-POD hilar study. J Gastroenterol Hepatol 2018; 33: 1146-1153 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jgh.14050?download=true
681 Komaya K, Ebata T, Yokoyama Y. et al. Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage: A propensity score matching analysis of resectable perihilar cholangiocarcinoma. Surgery 2017; 161: 394-404
682 Kim KM, Park JW, Lee JK. et al. A Comparison of Preoperative Biliary Drainage Methods for Perihilar Cholangiocarcinoma: Endoscopic versus Percutaneous Transhepatic Biliary Drainage. Gut Liver 2015; 9: 791-799 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625710/pdf/gnl-09-791.pdf
683 Kennedy TJ, Yopp A, Qin Y. et al. Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB (Oxford) 2009; 11: 445-451 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742615/pdf/hpb0011-0445.pdf
684 Miura S, Kanno A, Fukase K. et al. Preoperative biliary drainage of the hepatic lobe to be resected does not affect liver hypertrophy after percutaneous transhepatic portal vein embolization. Surg Endosc 2020; 34: 667-674 https://link.springer.com/content/pdf/10.1007/s00464-019-06813-y.pdf
685 Hintze RE, Abou-Rebyeh H, Adler A. et al. Magnetic resonance cholangiopancreatography-guided unilateral endoscopic stent placement for Klatskin tumors. Gastrointest Endosc 2001; 53: 40-46
686 Abraham NS, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc 2002; 56: 835-841
687 Paik WH, Park YS, Hwang JH. et al. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc 2009; 69: 55-62
688 Saluja SS, Gulati M, Garg PK. et al. Endoscopic or percutaneous biliary drainage for gallbladder cancer: a randomized trial and quality of life assessment. Clin Gastroenterol Hepatol 2008; 6: 944-950.e3 https://www.sciencedirect.com/science/article/abs/pii/S1542356508003418?via%3Dihub
689 Schima W, Prokesch R, Osterreicher C. et al. Biliary Wallstent endoprosthesis in malignant hilar obstruction: long-term results with regard to the type of obstruction. Clin Radiol 1997; 52: 213-219
690 Uberoi R, Das N, Moss J. et al. British Society of Interventional Radiology: Biliary Drainage and Stenting Registry (BDSR). Cardiovasc Intervent Radiol 2012; 35: 127-138 https://link.springer.com/content/pdf/10.1007/s00270-011-0103-4.pdf
691 Smith AC, Dowsett JF, Russell RC. et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344: 1655-1660
692 Speer AG, Cotton PB, Russell RC. et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2: 57-62
693 Almadi MA, Barkun A, Martel M. Plastic vs Self-Expandable Metal Stents for Palliation in Malignant Biliary Obstruction: A Series of Meta-Analyses. Am J Gastroenterol 2017; 112: 260-273
694 Lee TH, Moon JH, Choi JH. et al. Prospective comparison of endoscopic bilateral stent-in-stent versus stent-by-stent deployment for inoperable advanced malignant hilar biliary stricture. Gastrointest Endosc 2019; 90: 222-230 https://www.sciencedirect.com/science/article/abs/pii/S0016510719301737?via%3Dihub
695 Sharaiha RZ, Kumta NA, Desai AP. et al. Endoscopic ultrasound-guided biliary drainage versus percutaneous transhepatic biliary drainage: predictors of successful outcome in patients who fail endoscopic retrograde cholangiopancreatography. Surg Endosc 2016; 30: 5500-5505 https://link.springer.com/content/pdf/10.1007/s00464-016-4913-y.pdf
696 Paik WH, Lee TH, Park DH. et al. EUS-Guided Biliary Drainage Versus ERCP for the Primary Palliation of Malignant Biliary Obstruction: A Multicenter Randomized Clinical Trial. Am J Gastroenterol 2018; 113: 987-997
697 Bang JY, Navaneethan U, Hasan M. et al. Stent placement by EUS or ERCP for primary biliary decompression in pancreatic cancer: a randomized trial (with videos). Gastrointest Endosc 2018; 88: 9-17
698 Dumonceau JM, Tringali A, Papanikolaou IS. et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline – Updated October 2017. Endoscopy 2018; 50: 910-930 https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0659-9864.pdf
699 Moole H, Dharmapuri S, Duvvuri A. et al. Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review. Can J Gastroenterol Hepatol 2016; 2016: 4726078 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014937/pdf/CJGH2016-4726078.pdf
700 Zhao XQ, Dong JH, Jiang K. et al. Comparison of percutaneous transhepatic biliary drainage and endoscopic biliary drainage in the management of malignant biliary tract obstruction: a meta-analysis. Dig Endosc 2015; 27: 137-145 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/den.12320?download=true
701 Born P, Rösch T, Triptrap A. et al. Long-term results of percutaneous transhepatic biliary drainage for benign and malignant bile duct strictures. Scand J Gastroenterol 1998; 33: 544-549 https://www.tandfonline.com/doi/pdf/10.1080/00365529850172142?needAccess=true
702 De Palma GD, Galloro G, Siciliano S. et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001; 53: 547-553
703 Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 1998; 47: 354-362
704 Bulajic M, Panic N, Radunovic M. et al. Clinical outcome in patients with hilar malignant strictures type II Bismuth-Corlette treated by minimally invasive unilateral versus bilateral endoscopic biliary drainage. Hepatobiliary Pancreat Dis Int 2012; 11: 209-214
705 Cheng JL, Bruno MJ, Bergman JJ. et al. Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents. Gastrointest Endosc 2002; 56: 33-39
706 Vienne A, Hobeika E, Gouya H. et al. Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment. Gastrointest Endosc 2010; 72: 728-735
707 Rees J, Mytton J, Evison F. et al. The outcomes of biliary drainage by percutaneous transhepatic cholangiography for the palliation of malignant biliary obstruction in England between 2001 and 2014: a retrospective cohort study. BMJ Open 2020; 10: e033576 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045186/pdf/bmjopen-2019-033576.pdf
708 Harvey PR, Baldwin S, Mytton J. et al. Higher volume providers are associated with improved outcomes following ERCP for the palliation of malignant biliary obstruction. EClinicalMedicine 2020; 18: 100212 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948226/pdf/main.pdf
709 Tal AO, Vermehren J, Friedrich-Rust M. et al. Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction. World J Gastrointest Endosc 2014; 6: 13-19 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921441/pdf/WJGE-6-13.pdf
710 Moole H, Tathireddy H, Dharmapuri S. et al. Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: A systematic review and meta-analysis. World J Gastroenterol 2017; 23: 1278-1288 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323453/pdf/WJG-23-1278.pdf
711 Zoepf T, Jakobs R, Rosenbaum A. et al. Photodynamic therapy with 5-aminolevulinic acid is not effective in bile duct cancer. Gastrointest Endosc 2001; 54: 763-766
712 Ortner ME, Caca K, Berr F. et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125: 1355-1363 https://www.sciencedirect.com/science/article/abs/pii/S0016508503013623?via%3Dihub
713 Zoepf T, Jakobs R, Arnold JC. et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100: 2426-2430
714 Pereira SP, Jitlal M, Duggan M. et al. PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer. ESMO Open 2018; 3: e000379 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069917/pdf/esmoopen-2018-000379.pdf
715 Gonzalez-Carmona MA, Bolch M, Jansen C. et al. Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma. Aliment Pharmacol Ther 2019; 49: 437-447 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.15050?download=true
716 Wentrup R, Winkelmann N, Mitroshkin A. et al. Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma. Gut Liver 2016; 10: 470-475 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849702/pdf/gnl-10-470.pdf
717 Strand DS, Cosgrove ND, Patrie JT. et al. ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma. Gastrointest Endosc 2014; 80: 794-804
718 Dolak W, Schwaighofer H, Hellmich B. et al. Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. United European Gastroenterol J 2017; 5: 104-110 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384559/pdf/10.1177_2050640616654037.pdf
719 Kahaleh M, Mishra R, Shami VM. et al. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin Gastroenterol Hepatol 2008; 6: 290-297 https://www.sciencedirect.com/science/article/abs/pii/S1542356507011469?via%3Dihub
720 Ben-Josef E, Normolle D, Ensminger WD. et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005; 23: 8739-8747
721 Brunner TB, Blanck O, Lewitzki V. et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol 2019; 132: 42-47 https://www.sciencedirect.com/science/article/abs/pii/S0167814018336089?via%3Dihub
722 Tao R, Krishnan S, Bhosale PR. et al. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol 2016; 34: 219-226 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980564/pdf/JCO613778.pdf
723 Lee J, Yoon WS, Koom WS. et al. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol 2019; 195: 93-102 https://link.springer.com/content/pdf/10.1007/s00066-018-1367-2.pdf
724 Frakulli R, Buwenge M, Macchia G. et al. Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review. Br J Radiol 2019; 92: 20180688 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580923/pdf/bjr.20180688.pdf
725 Barney BM, Olivier KR, Miller RC. et al. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 2012; 7: 67 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464963/pdf/1748-717X-7-67.pdf
726 Tse RV, Hawkins M, Lockwood G. et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26: 657-664
727 Weiner AA, Olsen J, Ma D. et al. Stereotactic body radiotherapy for primary hepatic malignancies – Report of a phase I/II institutional study. Radiother Oncol 2016; 121: 79-85 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543719/pdf/nihms872134.pdf
728 Kopek N, Holt MI, Hansen AT. et al. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010; 94: 47-52
729 Schnapauff D, Denecke T, Grieser C. et al. Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2012; 35: 581-587 https://link.springer.com/content/pdf/10.1007/s00270-011-0249-0.pdf
730 Vogel A, Wege H, Caca K. et al. The diagnosis and treatment of cholangiocarcinoma. Dtsch Arztebl Int 2014; 111: 748-754 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239580/pdf/Dtsch_Arztebl_Int-111-0748.pdf
731 Horgan AM, Amir E, Walter T. et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012; 30: 1934-1940
732 Bridgewater J, Fletcher P, Palmer D. et al. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. J Clin Oncol 2022; 40 (18) 2048-2057 https://pubmed.ncbi.nlm.nih.gov/35316080/
733 Edeline J, Bonnetain F, Phelip JM. et al. Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. Journal of Clinical Oncology 2017; 35: 225-225 http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.225
734 Edeline J, Hirano S, Bertaut A. et al. Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies. Eur J Cancer 2022; 164: 80-87 https://pubmed.ncbi.nlm.nih.gov/35182925/
735 Luvira V, Satitkarnmanee E, Pugkhem A. et al. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma. Cochrane Database Syst Rev 2021; 9 (09) CD012814 https://pubmed.ncbi.nlm.nih.gov/34515993/
736 Oh DY, Ruth HeA, Qin S. et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence 2022; 1: EVIDoa2200015
737 Valle J, Wasan H, Palmer DH. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281 https://www.nejm.org/doi/pdf/10.1056/NEJMoa0908721?articleTools=true
738 Shroff RT, Javle MM, Xiao L. et al. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol 2019; 5: 824-830 https://jamanetwork.com/journals/jamaoncology/articlepdf/2730639/jamaoncology_shroff_2019_oi_190014.pdf
739 Shroff RT, Guthrie KA, Scott AJ. et al. SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. Journal of Clinical Oncology 2023; 41: LBA490
740 Okusaka T, Nakachi K, Fukutomi A. et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103: 469-474
741 Valle JW, Furuse J, Jitlal M. et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014; 25: 391-398
742 Park JO, Oh DY, Hsu C. et al. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat 2015; 47: 343-361 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509359/pdf/crt-2014-308.pdf
743 Markussen A, Jensen L, Diness L. et al. Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial. Cancers (Basel) 2020; 12 (07) https://pubmed.ncbi.nlm.nih.gov/32698410/
744 Valle JW, Borbath I, Khan SA. et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v28-v37 https://www.ncbi.nlm.nih.gov/pubmed/27664259
745 Kelley R, Ueno M, Yoo C. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; https://pubmed.ncbi.nlm.nih.gov/37075781/
746 Valle JW, Lamarca A, Goyal L. et al. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov 2017; 7: 943-962 https://cancerdiscovery.aacrjournals.org/content/candisc/7/9/943.full.pdf
747 Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15: 731-747 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419506/pdf/nihms-1016874.pdf
748 Solomon JP, Linkov I, Rosado A. et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 2020; https://www.ncbi.nlm.nih.gov/pubmed/31375766
749 Ross JS, Wang K, Gay L. et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014; 19: 235-242 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958461/pdf/theoncologist_13352.pdf
750 Drilon A, Laetsch TW, Kummar S. et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378: 731-739 https://www.nejm.org/doi/pdf/10.1056/NEJMoa1714448?articleTools=true
751 Oh DY, Bang YJ. HER2-targeted therapies – a role beyond breast cancer. Nat Rev Clin Oncol 2020; https://www.ncbi.nlm.nih.gov/pubmed/31548601
752 Neyaz A, Husain N, Gupta S. et al. Investigation of targetable predictive and prognostic markers in gallbladder carcinoma. J Gastrointest Oncol 2018; 9: 111-125 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848045/pdf/jgo-09-01-111.pdf
753 Javle M, Churi C, Kang HC. et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol 2015; 8: 58 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469402/pdf/13045_2015_Article_155.pdf
754 Czink E, Heining C, Weber TF. et al. [Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer]. Z Gastroenterol 2016; 54: 426-430 https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0042-103498
755 Javle M, Borad M, Azad N. et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2021; 22 (09) 1290-1300 https://pubmed.ncbi.nlm.nih.gov/34339623/
756 Hyman DM, Puzanov I, Subbiah V. et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015; 373: 726-736 https://www.nejm.org/doi/pdf/10.1056/NEJMoa1502309?articleTools=true
757 Salama AKS, Li SL, Macrae ER. et al. Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H. Journal of Clinical Oncology 2019; 37: URL
758 Lavingia V, Fakih M. Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review. J Gastrointest Oncol 2016; 7: E98-E102 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177579/pdf/jgo-07-06-E98.pdf
759 Kocsis J, Árokszállási A, András C. et al. Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion. J Gastrointest Oncol 2017; 8: E32-E38 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401859/pdf/jgo-08-02-E32.pdf
760 Bunyatov T, Zhao A, Kovalenko J. et al. Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV. J Gastrointest Oncol 2019; 10: 815-820 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657318/pdf/jgo-10-04-815.pdf
761 Subbiah V, Lassen U, Élez E. et al. Dabrafenib plus trametinib in patients with BRAF. Lancet Oncol 2020; 21 (09) 1234-1243 https://pubmed.ncbi.nlm.nih.gov/32818466/
762 Abou-Alfa G, Sahai V, Hollebecque A. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020; 21 (05) 671-684 https://pubmed.ncbi.nlm.nih.gov/32203698/
763 Abou-Alfa GK, Sahai V, Hollebecque A. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. The Lancet Oncology 2020; 21: 671-684
764 Javle M, Roychowdhury S, Kelley R. et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 2021; 6 (10) 803-815 https://pubmed.ncbi.nlm.nih.gov/34358484/
765 Goyal L, Meric-Bernstam F, Hollebecque A. et al. Futibatinib for. N Engl J Med 2023; 388 (03) 228-239 https://pubmed.ncbi.nlm.nih.gov/36652354/
766 Mazzaferro V, El-Rayes BF, Droz DitBusset M. et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer 2019; 120: 165-171 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342954/pdf/41416_2018_Article_334.pdf
767 Bahleda R, Italiano A, Hierro C. et al. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clin Cancer Res 2019; 25: 4888-4897 https://clincancerres.aacrjournals.org/content/clincanres/25/16/4888.full.pdf
768 Cleary J, Raghavan S, Wu Q. et al. Cancer Discov 2021; 11 (10) 2488-2505 https://pubmed.ncbi.nlm.nih.gov/33926920/
769 Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol 2019; https://www.ncbi.nlm.nih.gov/pubmed/30367139
770 Marabelle A, Le DT, Ascierto PA. et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology
771 Le DT, Durham JN, Smith KN. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357: 409-413 https://science.sciencemag.org/content/sci/357/6349/409.full.pdf
772 Le DT, Uram JN, Wang H. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372: 2509-2520 https://www.nejm.org/doi/pdf/10.1056/NEJMoa1500596?articleTools=true
773 Goeppert B, Roessler S, Renner M. et al. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. Br J Cancer 2019; 120: 109-114 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325153/pdf/41416_2018_Article_199.pdf
774 Maio M, Ascierto P, Manzyuk L. et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022; 33 (09) 929-938 https://pubmed.ncbi.nlm.nih.gov/35680043/
775 Zhu A, Macarulla T, Javle M. et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol 2021; 7 (11) 1669-1677 https://pubmed.ncbi.nlm.nih.gov/34554208/
776 Abou-Alfa GK, Macarulla T, Javle MM. et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology 2020; 21: 796-807
777 Lamarca A, Palmer D, Wasan H. et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021; 22 (05) 690-701 https://pubmed.ncbi.nlm.nih.gov/33798493/
778 Choi I, Kim K, Lee J. et al. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. Eur J Cancer 2021; 154: 288-295 https://pubmed.ncbi.nlm.nih.gov/34303267/
779 Zheng Y, Tu X, Zhao P. et al. A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin. Br J Cancer 2018; 119 (03) 291-295 https://pubmed.ncbi.nlm.nih.gov/29955136/
780 Yoo C, Kim K, Jeong J. et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol 2021;
781 Vogel A, Wenzel P, Folprecht G. et al. 53MO Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116). Annals of Oncology 2022; 33: S563
782 Ramaswamy A, Ostwal V, Sharma A. et al. Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT). JAMA Oncol 2021; 7 (03) 436-439 https://pubmed.ncbi.nlm.nih.gov/33270098/
783 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK). Entwicklung von leitlinienbasierten Qualitätsindikatoren Methodenpapier für das Leitlinienprogramm Onkologie, Version 21. 2017 https://www.leitlinienprogramm-onkologie.de/methodik/grundlegende-informationen-zur-methodik
784 Ashoori N, Bamberg F, Paprottka P. et al. Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation. Digestion 2012; 86: 338-348
785 Boteon A, Boteon YL, Vinuela EF. et al. The impact of transarterial chemoembolization induced complications on outcomes after liver transplantation: A propensity-matched study. Clin Transplant 2018; 32: e13255
786 Habibollahi P, Shamchi SP, Choi JM. et al. Association of Complete Radiologic and Pathologic Response following Locoregional Therapy before Liver Transplantation with Long-Term Outcomes of Hepatocellular Carcinoma: A Retrospective Study. J Vasc Interv Radiol 2019; 30: 323-329 https://www.sciencedirect.com/science/article/pii/S105104431831741X?via%3Dihub
787 Lu DS, Yu NC, Raman SS. et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41: 1130-1137
788 Nicolini A, Martinetti L, Crespi S. et al. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 327-332
789 Sandow T, Pavlus J, Field D. et al. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort. J Vasc Interv Radiol 2019; 30: 995-1003
790 Tan CHN, Yu Y, Tan YRN. et al. Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere?. Ann Hepatobiliary Pancreat Surg 2018; 22: 27-35
791 Werner JD, Frangakis C, Ruck JM. et al. Neoadjuvant Transarterial Chemoembolization Improves Survival After Liver Transplant in Patients With Hepatocellular Carcinoma. Exp Clin Transplant 2019; 17: 638-643
792 Sapisochin G, Barry A, Doherty M. et al. Stereotactic body radiotherapy vs TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma An intention-to-treat analysis. J Hepatol 2017; 67: 92-99
793 Wang JH, Wang CC, Hung CH. et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 2012; 56: 412-418 https://www.journal-of-hepatology.eu/article/S0168-8278(11)00524-1/fulltext
794 Peng ZW, Lin XJ, Zhang YJ. et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology 2012; 262: 1022-1033
795 Hasegawa K, Kokudo N, Makuuchi M. et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2013; 58: 724-729 https://www.sciencedirect.com/science/article/pii/S016882781200877X?via%3Dihub
796 Fang Y, Chen W, Liang X. et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 193-200 https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.12441
797 Miura JT, Johnston FM, Tsai S. et al. Surgical resection versus ablation for hepatocellular carcinoma ≤ 3 cm: a population-based analysis. HPB (Oxford) 2015; 17: 896-901 https://www.hpbonline.org/article/S1365-182X(15)31122-9/pdf
798 Zhang M, Ma H, Zhang J. et al. Comparison of microwave ablation and hepatic resection for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther 2017; 10: 4829-4839 https://pubmed.ncbi.nlm.nih.gov/29042794/
799 Zhang QB, Zhang XG, Jiang RD. et al. Microwave ablation versus hepatic resection for the treatment of hepatocellular carcinoma and oesophageal variceal bleeding in cirrhotic patients. Int J Hyperthermia 2017; 33: 255-262 https://www.tandfonline.com/doi/pdf/10.1080/02656736.2016.1257824?needAccess=true
800 Liu PH, Hsu CY, Hsia CY. et al. Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2 cm in a Propensity Score Model. Ann Surg 2016; 263: 538-545 https://www.ingentaconnect.com/content/wk/sla/2016/00000263/00000003/art00040;jsessionid=1n53m5b4ljd7b.x-ic-live-01
801 Takayasu K, Arii S, Sakamoto M. et al. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting. Liver Int 2018; 38: 484-493 https://onlinelibrary.wiley.com/doi/abs/10.1111/liv.13670
802 Hung HH, Chiou YY, Hsia CY. et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol 2011; 9: 79-86 https://www.cghjournal.org/article/S1542-3565(10)00847-5/pdf
803 Ogihara M, Wong LL, Machi J. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. HPB (Oxford) 2005; 7: 214-221
804 Lü MD, Kuang M, Liang LJ. et al. [Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial]. Zhonghua Yi Xue Za Zhi 2006; 86: 801-805
805 Lupo L, Panzera P, Giannelli G. et al. Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection?. HPB (Oxford) 2007; 9: 429-434
806 Abu-Hilal M, Primrose JN, Casaril A. et al. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg 2008; 12: 1521-1526
807 Tashiro H, Aikata H, Waki K. et al. Treatment strategy for early hepatocellular carcinomas: comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection. J Surg Oncol 2011; 104: 3-9
808 Kim JW, Shin SS, Kim JK. et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection. Korean J Radiol 2013; 14: 626-635
809 Tang C, Shen J, Feng W. et al. Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Medicine (Baltimore) 2016; 95: e3754 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902444/pdf/medi-95-e3754.pdf
810 Bholee AK, Peng K, Zhou Z. et al. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. Clin Transl Oncol 2017; 19: 844-852
811 Pan T, Mu LW, Wu C. et al. Comparison of Combined Transcatheter Arterial Chemoembolization and CT-guided Radiofrequency Ablation with Surgical Resection in Patients with Hepatocellular Carcinoma within the Up-to-seven Criteria: A Multicenter Case-matched Study. J Cancer 2017; 8: 3506-3513 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687165/pdf/jcav08p3506.pdf
812 Zhang R, Shen L, Zhao L. et al. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol 2018; 24: 219-224 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045511/pdf/dir-24-4-219.pdf
813 Lin DY, Liaw YF, Lee TY. et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial. Gastroenterology 1988; 94: 453-456 https://www.sciencedirect.com/science/article/abs/pii/0016508588904362?via%3Dihub
814 Pelletier G, Roche A, Ink O. et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-184
815 A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-1261 https://www.nejm.org/doi/pdf/10.1056/NEJM199505113321903?articleTools=true
816 Bruix J, Llovet JM, Castells A. et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-1583 https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.510270617?download=true
817 Pelletier G, Ducreux M, Gay F. et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial Groupe CHC. J Hepatol 1998; 29: 129-134
818 Stefanini GF, Amorati P, Biselli M. et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma An Italian experience. Cancer 1995; 75: 2427-2434 https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2819950515%2975%3A10%3C2427%3A%3AAID-CNCR2820751007%3E3.0.CO%3B2-J?download=true
819 Bronowicki JP, Vetter D, Dumas F. et al. Transcatheter oily chemoembolization for hepatocellular carcinoma A 4-year study of 127 French patients. Cancer 1994; 74: 16-24 https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2819940701%2974%3A1%3C16%3A%3AAID-CNCR2820740105%3E3.0.CO%3B2-V?download=true
820 Kim JH, Yoon HK, Kim SY. et al. Transcatheter arterial chemoembolization vs chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther 2009; 29: 1291-1298 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2036.2009.04016.x?download=true
821 Herber S, Otto G, Schneider J. et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2007; 30: 1156-1165 https://link.springer.com/content/pdf/10.1007/s00270-007-9032-7.pdf
822 Chung GE, Lee JH, Kim HY. et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011; 258: 627-634
823 Georgiades CS, Hong K, DʼAngelo M. et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16: 1653-1659 https://www.sciencedirect.com/science/article/pii/S1051044307607933?via%3Dihub
824 Okazaki M, Higashihara H, Koganemaru H. et al. Transcatheter arterial embolization for inoperable hepatocellular carcinoma. Jpn J Clin Radiol 1991; 36: 535-539
825 Sacco R, Bargellini I, Bertini M. et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22: 1545-1552
826 van Malenstein H, Maleux G, Vandecaveye V. et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34: 368-376 https://www.karger.com/Article/Pdf/329602
827 Dhanasekaran R, Kooby DA, Staley CA. et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101: 476-480 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jso.21522?download=true
828 Ferrer Puchol MD, la Parra C, Esteban E. et al. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. Radiologia 2011; 53: 246-253 https://www.sciencedirect.com/science/article/abs/pii/S0033833810003449?via%3Dihub
829 Wiggermann P, Sieron D, Brosche C. et al. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs TACE with cisplatin/lipiodol (cTACE). Med Sci Monit 2011; 17: Cr189-Cr195 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539521/pdf/medscimonit-17-4-cr189.pdf
830 Song MJ, Chun HJ, Song DS. et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244-1250
831 Megías VericatJE, García MarcosR, López BrizE. et al. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. Radiologia 2015; 57: 496-504 https://www.sciencedirect.com/science/article/abs/pii/S0033833815000764?via%3Dihub
832 Kloeckner R, Weinmann A, Prinz F. et al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 2015; 15: 465
833 Facciorusso A, Mariani L, Sposito C. et al. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 2016; 31: 645-653 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jgh.13147?download=true
834 Baur J, Ritter CO, Germer CT. et al. Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma. Hepat Med 2016; 8: 69-74 https://pubmed.ncbi.nlm.nih.gov/27382341/
835 Gao S, Yang Z, Zheng Z. et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013; 60: 813-820
836 Huang K, Zhou Q, Wang R. et al. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 920-925 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jgh.12439?download=true
837 Zhou X, Tang Z, Wang J. et al. Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis. Int J Clin Exp Med 2014; 7: 3892-3903
838 Zou JH, Zhang L, Ren ZG. et al. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis 2016; 17: 510-517 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1751-2980.12380?download=true
839 Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Dig Liver Dis 2016; 48: 571-577
840 Celotti A, Solaini L, Montori G. et al. Preoperative biliary drainage in hilar cholangiocarcinoma: Systematic review and meta-analysis. Eur J Surg Oncol 2017; 43: 1628-1635
841 Ramanathan R, Borrebach J, Tohme S. et al. Preoperative Biliary Drainage Is Associated with Increased Complications After Liver Resection for Proximal Cholangiocarcinoma. J Gastrointest Surg 2018; 22: 1950-1957 https://link.springer.com/content/pdf/10.1007/s11605-018-3861-3.pdf
842 Cai Y, Tang Q, Xiong X. et al. Preoperative biliary drainage versus direct surgery for perihilar cholangiocarcinoma: A retrospective study at a single center. Biosci Trends 2017; 11: 319-325 https://www.jstage.jst.go.jp/article/bst/11/3/11_2017.01107/_pdf
843 Farges O, Regimbeau JM, Fuks D. et al. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 2013; 100: 274-283 https://bjssjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bjs.8950?download=true
844 Xiong JJ, Nunes QM, Huang W. et al. Preoperative biliary drainage in patients with hilar cholangiocarcinoma undergoing major hepatectomy. World J Gastroenterol 2013; 19: 8731-8739 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870521/pdf/WJG-19-8731.pdf
845 Wang L, Lin N, Xin F. et al. A systematic review of the comparison of the incidence of seeding metastasis between endoscopic biliary drainage and percutaneous transhepatic biliary drainage for resectable malignant biliary obstruction. World J Surg Oncol 2019; 17: 116 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612106/pdf/12957_2019_Article_1656.pdf
846 Kishi Y, Shimada K, Nara S. et al. The type of preoperative biliary drainage predicts short-term outcome after major hepatectomy. Langenbecks Arch Surg 2016; 401: 503-511 https://link.springer.com/content/pdf/10.1007/s00423-016-1427-y.pdf
847 Sangchan A, Kongkasame W, Pugkhem A. et al. Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial. Gastrointest Endosc 2012; 76: 93-99